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ABSTRACT
Bredahl, Eric C. Effects of Resistance Training and Creatine Monohydrate on
Doxorubicin-Induced Muscle Dysfunction. Published Doctor of Philosophy
dissertation, University of Northern Colorado, 2015.
Doxorubicin (DOX) is a powerful chemotherapy agent that is associated with a
number of deleterious side effects, including skeletal muscle dysfunction. The exact
mechanisms behind the observed skeletal muscle dysfunction have yet to be fully
understood. Nonetheless, the observed myotoxicity is believed to be the result of an
increased oxidative stress. Resistance training (RT) has been shown to preserve skeletal
muscle function in DOX treated muscles. Conversely, creatine (Cr) has been shown to
improve skeletal muscle function. Yet, there has been no investigation into the effect of
combined RT and Cr on DOX-induced muscle dysfunction. Thus, the possibility exists
that in combination, Cr and RT could attenuate the myotoxic effects of DOX beyond that
of when the interventions are administered separately. PURPOSE: To investigate the
effects of prior RT and Cr treatment on DOX-induced skeletal muscle dysfunction.
METHODS: Male Sprague-Dawley rats were randomly assigned to a RT or sedentary
group. Resistance training was simulated by using an elevated food model. After six
weeks of training, the soleus (SOL) and extensor digitorum longus (EDL) were excised
and placed in an ex vivo tissue bath containing a Krebs buffer (K) where initial force was
measured. Muscles were then incubated with either K or a K containing Cr (25 mM) for
30 minutes. The buffers were refreshed with either new K or K containing DOX (24 μM)
and incubated for 30 minutes. Muscles were then supplied with new K and twitch force
iii

data were collected. The muscles were again supplied with fresh K and subjected to a
100 sec fatigue protocol where force production was recorded every 10 seconds to
analyze fatigue. After functional data were collected, tissues were analyzed for total Cr
content. RESULTS: This study failed to demonstrate DOX-induced muscle dysfunction
on maximal twitch characteristics but DOX-induced dysfunction did become apparent
under prolonged stimulation. Furthermore, this investigation demonstrated that, in
combination, RT and Cr could significantly attenuate fatigue in the DOX treated muscle.
This study also failed to show any significant change total intracellular Cr after
incubation with Cr or prior RT. CONCLUSION: Evidence from this study provides
insight into the effectiveness of a combined treatment with RT and Cr to minimize
fatigue and offset the myotoxic effects of DOX. Such evidence provides more support to
the effectiveness and capacity of exercise interventions to improve functioning of cancer
patients during their treatment process.
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CHAPTER I
INTRODUCTION
The use of exercise as a means of minimizing cancer related fatigue and
improving quality of life during and after chemotherapy treatment is becoming more
commonplace. With this growing trend toward improving quality of life and reducing
patient fatigue during and after chemotherapy, there is an immense need to develop safe
and effective guidelines based on quality research.
Fatigue is one of the most common side effects of cancer treatment. Up to 70%
of patients experience fatigue during chemotherapy and radiation therapy (Smets,
Garssen, Schuster-Uitterhoeve, & de Haes, 1993). Additionally, many cancer patients
suffer severe limitations in their ability to perform activities of daily living (ADLs).
These activities include feeding, bathing, dressing, grooming, work, and homemaking.
There is also evidence that fatigue can adversely affect the efficacy of chemotherapy;
fatigue as a side effect can be a reason to slow or stop treatment altogether. In recent
years, there has been a large amount of information encouraging cancer patients to
exercise prior to and during chemotherapy treatment. Existing research has found that
exercise is particularly effective during treatment with the chemotherapeutic drug
doxorubicin (DOX), which is classified as an anthracycline.
Anthracyclines are arguably the most effective and commonly prescribed
antineoplastic chemotherapy drugs (Weiss, 1992). They are used to treat numerous types
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of solid tumors (Green et al., 2001), leukemias (Lipshultz et al., 2004), and lymphomas
(Abraham, Basser, & Green, 1996). Anthracyclines are named based on their chemical
structures, which consist of an anthraquinone-chromophore and the polycyclic ring
system (Weiss, 1992). To date, there are more than 2,000 analogs of anthracyclines;
however, only four analogs of anthracyclines are used clinically. Of these four, DOX
stands alone in its effectiveness and commonality.
Doxorubicin can be traced back to 1958 when Farmitalia Research Laboratories
of Milan, Italy, discovered an antibiotic (daunomycin) derived from a new species of
Streptomyces peucetius (Di Marco et al., 1964). A few years later, the laboratory of
Rhone-Poulenc in France also publicized a new antibiotic (rubidomyocin) from a
different species of Streptomyces peucetius (Dubost et al., 1964). Both laboratories had
uncovered the exact same substance, and the antibiotic was subsequently named DNR
(Weiss, 1992). In 1964, DNR was approved to treat leukemia and lymphoma (Weiss,
1992). Farmitalia laboratory researchers then created DOX from a 14-hydroxy analog of
DNR derived from a mutant form of Streptomyces peucetius (Arcamone et al., 1969),
although it was not until 1974 that cancer patients in the United States started receiving
DOX as a chemotherapy treatment (Weiss, 1992). Although the structures of DOX and
DNR are very similar, the antitumor activity of DOX is more potent than that of DNR (Di
Marco, Gaetani, & Scarpinato, 1969), and the spectrum of antineoplastic activities of
DOX are much wider than those of DNR (Weiss, 1992).
Despite the positive anticancer effects of DOX, it was not until years later that
scientists learned about its damaging side effects. The first report of DOX-induced
cardiotoxicity was reported in 1973. It was characterized by deterioration of the
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myocardium, assessed through echocardiograms and postmortem examinations (Lefrak,
Pitha, Rosenheim, & Gottlieb, 1973). Later on it was discovered that DOX given at high
doses (550mg/m2) was associated with an increased incidence of heart failure (Swain,
Whaley, & Ewer, 2003). As DOX use became more prolific, so did the evidence
suggesting that it had a negative effect on more systems beyond that of the cardiovascular
system (Goorin et al., 1990; Haq et al., 1985; Von Hoff et al., 1979).
As DOX use increased, so did clinicians’ reports that its use was associated with a
higher than average incidence of fatigue (Gilliam & St Clair, 2011). These reports of
excessive fatigue were generally attributed to the cardiotoxic effects of DOX. As
researchers became more aware of DOX’s toxic effects on various physiological systems,
they began to understand that fatigue could not be attributed to reductions in the
cardiovascular system alone. Later, multiple investigators discovered that DOX does, in
fact, exert a myotoxic effect that can interfere with normal skeletal muscle function
(Hydock, Lien, Jensen, Schneider, & Hayward, 2011).
As researchers gained a better understanding of DOX, they searched to identify a
means of overcoming its cardiotoxic side effects. To date, one of the most effective
treatments capable of attenuating DOX-induced cardiotoxicity is with aerobic exercise
(Chicco, Schneider, & Hayward, 2005; Hydock, Lien, Schneider, & Hayward, 2008;
Wonders, Hydock, Schneider, & Hayward, 2008).
The ability to reduce the myotoxic effects of DOX could make a difference in a
patient’s ability to perform ADLs and maintain a degree of normalcy in his or her life. If
true, this could greatly alter the patient’s outlook on life and could mean the difference
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between living independently or becoming dependent on others, which has a profound
impact on a patient’s quality of life.
Clinically, DOX administration results in a number of harmful effects to skeletal
muscle, including weakness (Harada et al., 2004), reduced functional capacity (Gilliam &
St Clair, 2011), reduced fiber size (Bonifati et al., 2000), increased rates of atrophy
(Pfeiffer et al., 1997), and reduced body weight (Tozer et al., 2008). If these myotoxic
effects can be mitigated, it might be possible to minimize cancer related fatigue, improve
the cancer patient’s quality of life, and increase his or her capacity to perform activities of
daily living.
Perhaps no treatment is better suited to minimize these effects than with a form of
resistance training (RT). Resistance training has been shown to increase fiber size (Mero
et al., 2013), increase maximal strength in cancer patients (De Backer, Schep, Backx,
Vreugdenhil, & Kuipers, 2009), minimize cancer related fatigue (Segal et al., 2003), and
improve bone mineral density (Layne & Nelson, 1999). All of these adaptations stand in
stark contrast to the myotoxic effects of DOX. Thus, it might be possible to mitigate the
DOX-induced muscle dysfunction with a form of RT.
Previous research has shown that cardiac tissue is particularly sensitive to
treatment with DOX (Hayward & Hydock, 2007; Ito et al., 1990). Subsequently,
research has also demonstrated that DOX-induced cardiotoxicity can be attenuated by
various forms of aerobic exercise (Chicco, Hydock, Schneider, & Hayward, 2006; Chicco
et al., 2005; Hydock et al., 2008; Wonders et al., 2008). There are reports that DOX will
also affect skeletal muscle. One such report demonstrated that DOX treatment increased
calcium (Ca2+) release from the sarcoplasmic reticulum (SR; Abramson et al., 1988).
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Other reports have claimed that along with a rise in free intracellular Ca2+, there is a
decrease in the antioxidant capabilities of the cell, leading to an increase in free radical
production (Doroshow, Tallent, & Schechter, 1985; Kanter, Hamlin, Unverferth, Davis,
& Merola, 1985; Smuder, Kavazis, Min, & Powers, 2011; Wallace, 2003). Taken
together, this rise in free intracellular Ca2+ is likely the result of oxidative damage to the
SR, a reduced energy supply for SR Ca2+ uptake via compromised mitochondria, and
alterations in the contractile properties of skeletal muscle. Thus, any treatment that could
act as a short-term energy buffer could minimize the energy deficit caused by DOX.
For instance, creatine monohydrate (Cr) could be used to help minimize DOXinduced muscle dysfunction. The benefits of Cr as an ergogenic aid have been well
documented (Clark, 1997; Kreider, 2003; Persky & Brazeau, 2001). It has the ability to
improve muscular performance (Volek et al., 1997), enhance the phosphocreatine energy
system (Persky & Brazeau, 2001), increase total Cr (Bemben & Lamont, 2005), and act
as a mild antioxidant (Lawler, Barnes, Wu, Song, & Demaree, 2002). Because of these
properties, Cr could be used as a possible approach to overcome DOX-induced muscle
dysfunction. One of the key points of this study was to examine the role of Cr treatment
on DOX-induced muscle dysfunction. If effective, it could be used as the first step on the
road for its use as a possible nutraceutical to help alleviate the harmful effects of DOX.
Statement of the Purpose
The purpose of this study was fourfold: (a) to examine the effects of RT on DOXinduced muscle dysfunction and; (b) to investigate the effects of Cr on DOX-induced
muscle dysfunction; (c) to investigate the combined effects of Cr and RT on DOX-
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induced muscle dysfunction; and (d) to investigate the effects of RT and Cr on total Cr
concentration.
Research Hypotheses
H1

Resistance training will protect against doxorubicin-induced myotoxicity
by preserving maximal twitch force and attenuating fatigue.

H2

Creatine treatment will protect against doxorubicin-induced myotoxicity
by preserving maximal twitch force and reducing fatigue.

H3

Combined resistance training and creatine treatment will provide
additional protection against doxorubicin-induced dysfunction when
compared to resistance training and creatine administered alone.

H4

Creatine treatment will increase in the total creatine concentration.
Need for the Study

Treatment with doxorubicin is associated with a number of debilitating side
effects, such as its dose dependent cardiotoxicity and more recently discovered
myotoxicity. The cardiotoxicity is commonly manifested in the form of dilated
cardiomyopathy and congestive heart failure (Chatterjee, Zhang, Honbo, & Karliner,
2010). The mechanisms behind these negative effects are the result of an increase in
oxidative stress, increase in intracellular iron, inhibition of NRG1/Erb signaling cascade,
impairment of progenitor cell renewal and cardiac repair, and decreased vasculogenesis
(Menna, Salvatorelli, & Minotti, 2008; Shi, Moon, Dawood, McManus, & Liu, 2011).
To date, there is not an effective pharmacological agent that has the ability to prevent
these side effects. However, aerobic exercise has been used effectively as a means for
attenuating the decline in cardiac function (Chicco et al., 2005; Hydock et al., 2008;
Wonders et al., 2008).
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There is growing evidence that DOX also negatively affects skeletal muscle
function (Ascensao et al., 2011; Hydock et al., 2011; van Norren et al., 2009). Although
there is consensus that DOX has a negative impact on skeletal muscle function, the
mechanisms behind the dysfunction remain elusive (Gilliam & St Clair, 2011). A
number of mechanisms have been proposed to explain DOX-induced dysfunction. It has
been suggested that the dysfunction could be a result of variations in tumor necrosis
factor receptors (Gilliam & St Clair, 2011), changes in Ca2+ handling (van Norren et al.,
2009), and disruptions in the SR (Abramson, Buck, Salama, Casida, & Pessah, 1988).
Another possibility is that DOX could be interfering with key Ca2+ handling proteins such
as the sarcoendoplasmic reticulum calcium ATPase (SERCA), which is instrumental in
Ca2+ uptake during skeletal muscle relaxation (Periasamy & Kalyanasundaram, 2007). In
cardiac tissue treated with DOX, there is a decrease in the antioxidant capabilities of the
cardiac myocytes (Wallace, 2003). In diaphragm muscle treated with DOX, there is a
similar reduction in antioxidant capabilities (Gilliam, Moylan, Callahan, Sumandea, &
Reid, 2011). This idea is further evidenced by the activation of caspase-3, a key
regulatory component of apoptosis triggered by high levels of oxidative stress (Smuder,
et al., 2011). The increase in free radical production could lead to an altered functional
capacity of the SR, possibly through lipid peroxidation. Furthermore, this altered Ca2+
handling via damaged SR could be a factor in the increased muscular fatigue commonly
seen during DOX treatment.
In regard to the proposed mechanisms of DOX-induced muscle dysfunction, Cr
can serve as a possible means of attenuating the DOX-induced muscle dysfunction.
Creatine is a very popular ergogenic aid and its benefits on the phosphagen system have
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been well studied (Clark, 1997; Kraemer & Volek, 1999; Persky & Brazeau, 2001).
Creatine has been shown to increase muscular performance variables in combination with
short-term, high intensity exercise (Persky & Brazeau, 2001). Other research has
demonstrated that when a skeletal muscle is incubated in an ex vivo tissue bath with Cr,
there is an increased force production and improved rates of time to fatigue (Head,
Greenaway, & Chan, 2011). It has also been shown that supplemental Cr can improve
the rates of muscle fatigue in mice with mitochondrial dysfunction (Eisner, Lenaers, &
Hajnoczky, 2014).
Part of this study examined the effects of incubating muscles ex vivo with Cr prior
to treatment with DOX. This treatment, in combination with RT, had the possibility of
attenuating DOX-induced myotoxicity. This study is the first step in establishing
guidelines for improving the quality of life for those with DOX-induced muscle
dysfunction. To date, there is a gap in the literature as to the effects that RT has on DOX
treated skeletal muscle with and without Cr supplementation. It is important for there to
be a better scientific understanding of these factors since RT and Cr supplementation may
be an effective treatment strategy in the palliative care of those undergoing chemotherapy
with DOX. Table 1.1 provides abbreviations pertinent to this study.
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Table 1.1
Abbreviations
Acronym
ADLs
ADP
AGAT
AKT
AMP
ARE
ATP
Ca2+
CAT
CK
Cr
CreaT
DNA
DOX
EDL
FOKO
GMAT
GPX
IGF
K
KEAP1
MAPK
mTOR
NADH
Nrf2
PCr
P70 S6K
ROS
SERCA
SOD
SOL
SR

Definition
Activities of daily living
Adenosine diphosphate
Arginine glycine aminotransferase
Protein kinase b
Adenosine monophosphate
Antioxidant response element
Adenosine triphosphate
Calcium
Catalase
Creatine kinase
Creatine monohydrate
Creatine transporter
Deoxyribonucleic acid
Doxorubicin
Extensor digitorum longus
Fox-head box O
Guanidinoacetate methyltransferase
Glutathione peroxidase
1- insulin like growth factor 1
Krebs-Henseleit buffer
Kelch-like ECH-associated protein 1
Mitogen activated protein kinases
Mammalian target of rapmaycin
Nicotinamide adenine dinucleotide
Nuclear like factor 2
Phosphocreatine
Ribosomal protein S6K
Reactive oxygen species
Sarco/endoplasmic reticulum calcium-ATPase
Super oxide dismutase
Soleus
Sarcoplasmic reticulum
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Delimitations of the Study
Samples in this study were collected form 10 week-old male Sprague Dawley
rats. Resistance training was simulated by using an elevated food and water model for
six weeks. Skeletal muscle function was assessed using an ex vivo muscle function
apparatus. Muscle dysfunction was induced by incubating excised skeletal muscle tissue
in a 25µM DOX+Krebs-Henseleit (K) solution. Creatine was added to the incubating
buffers at a concentration of 25 mM prior to DOX treatment.
Definition of Terms
Apoptosis. Programed cell death.
Creatine monohydrate. Synthetic form of creatine.
Doxorubicin. Chemotherapy agent approved by the Food and Drug
Administration for the treatment of a wide variety of cancers.
Fatigue rate. Recording over time of the ability of a muscle to produce a less
than anticipated response for a given stimulus.
Lipid peroxidation. Oxidative degradation of lipids.
Maximal twitch force. Highest recorded contractile response.
Protein carbonyl. Modification of amino acids side chains in proteins to
carbonyl derivatives.
Rate of force decline. Rate at which a muscle relaxes from a contraction
following stimulation.
Rate of force development. Rate at which a muscle develops contractile
strength.
Reactive oxygen species. Chemically reactive molecules containing oxygen.

CHAPTER II

REVIEW OF LITERATURE
Cancer is an ever-growing threat to human life and longevity. As humans
continue to surpass their life expectancy, the risk of cancer becomes ever more prevalent.
Males have a 43.2% chance of developing cancer in their lifetime, whereas females have
a 38% chance of developing cancer (Howlader et al., 2013). This cancer prevalence
requires treatments that are versatile and effective.
One such treatment is the chemotherapy agent known as doxorubicin (DOX).
Doxorubicin is an anthracycline antibiotic commonly used in the treatment of a wide
range of cancers including leukemia, lymphoma, many types of carcinoma, and soft
tissue sarcomas (Tacar, Sriamornsak, & Dass, 2013). Despite the therapeutic benefits of
DOX, it also comes with a number of negative side effects that, if left unchecked, could
severely alter the ability of the patient to perform activities of daily living (ADLs), and in
some cases, even become life threatening (Martin, Vogel, Crown, & Mackey, 2005).
These adverse side effects can become apparent within 2-3 days of administration
(Chatterjee et al., 2010).
The most common side effects of DOX treatment include nausea, vomiting,
neutropenia, alopecia, arrhythmias, heart failure, and skeletal muscle dysfunction
(Greene, Nail, Fieler, Dudgeon, & Jones, 1994; Hydock et al., 2011; Shi, Moon, Dawood,
Mcmanus, & Liu, 2011). Skeletal muscle dysfunction is of particular concern because of
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its direct involvement ADLs and is relatively common in those patients undergoing
treatment with DOX (Jennings-Sanders & Anderson, 2003; Schwartz, 2000; Smuder et
al., 2011).
All ADLs involve varying degrees of skeletal muscle activity. Although these
tasks are typically comprised of short bursts of activity, they are often taken for granted
in healthy populations. However, in the patient undergoing chemotherapy, being unable
to perform ADLs can have a profound effect on quality of life (Fukuse, Satoda, Hijiya, &
Fujinaga, 2005; Jacobsen et al., 1999).
Doxorubicin
Doxorubicin exerts its antitumor activity through two main methods. First, DOX
inhibits DNA Topoisomerase II, which prevents DNA replication (Tewey, Rowe, Yang,
Halligan, & Liu, 1984). Secondly, DOX generates reactive oxygen species (ROS)
leading to cellular, organelle and DNA damage. In addition, there is evidence that
generation of ROS can lead to apoptotic cell death through activation of p53-DNA
binding and activation of the intrinsic cascade (Janeesh & Abraham, 2014).
Reactive oxygen species are chemically reactive molecules that are generated
from a variety of sources (Kohen & Nyska, 2002). While ROS are implicated as
signaling molecules that help to maintain physiological homeostasis, excessive
production of these ROS may overwhelm endogenous antioxidant defense mechanisms,
leading to oxidative modification of key cellular macromolecules (Deavall, Martin,
Horner, & Roberts, 2012) and possibly membrane damage through lipid peroxidation
(Halliwell & Chirico, 1993). In the cancer cell, this is beneficial because it can
eventually lead to apoptosis. But in healthy tissue, this is a cause of concern, especially
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in cardiac and skeletal muscle cells. Doxorubicin has also been shown to increase the
freely available amount of intracellular iron (Xu, Presson, & Richardson, 2005). This is
important because as intracellular iron increases, it begins to form a redox cycle with the
appropriate electron donors in the mitochondria, which can lead to the formation of
superoxide at complex Ӏ in the electron transport chain (Berthiaume & Wallace, 2007).
This disruption of mitochondrial function could eventually reduce the availability of
adenosine triphosphate (ATP) and possibly interfere with energy-dependent actions of the
cell.
Doxorubicin is unique because its structure allows for the formation of a
semiquinone through loss of an electron (Zucchi & Danesi, 2003). This reduction is the
result of exogenous nicotinamide adenine dinucleotidedehydrogenase (NADH) in the
mitochondria. The formation of the semiquinone can then donate an electron to oxygen,
which forms a superoxide anion. The production of superoxide molecules could be a
possible mechanism for lipid peroxidation. Lipid peroxidation has been found to be
increased by as much as four times in the DOX treated cell (Mimnaugh, Trush,
Bhatnagar, & Gram, 1985). This suggests DOX can damage lipid bound organelles,
further disrupting normal cellular function.
Lipid peroxidation is an important process in many disease states in both adults
and infants (Mylonas & Kouretas, 1999). The process of lipid peroxidation does take
place in small amounts in the human body, but in excess, it can lead to severe organelle
dysfunction. With lipid peroxidation, ROS readily attack the polyunsaturated fatty acids
of any fatty acid membrane, which leads to a domino effect of continuous oxidation
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(Mylonas & Kouretas, 1999). The destruction of membrane lipids and the end products
of such lipid peroxidation reactions are especially dangerous for the viability of cells.
Natural antioxidants such as superoxide dismutase (SOD) and catalase (CAT) can
quickly be overwhelmed, causing a continual process of lipid peroxidation to take place
(Mukhopadhyay, Ghosh, & Chatterjee, 1995). Since lipid peroxidation is a chain
reaction, the initial oxidation of only a few lipid molecules can result in significant cell
damage or cell death (Deviatkina, Tarasenko, & Voskresenskii, 1984; Mylonas &
Kouretas, 1999).
Although ROS are important in maintaining normal physiological function, in
excess they can lead to severe damage of cellular components (Valko et al., 2007).
Normally, the generation of ROS is balanced by antioxidant defense systems regulated by
a web of pathways to ensure the correct response. Nuclear like factor 2 (Nrf2) is the
primary regulator of cellular resistance to ROS (de Grey, 2000; Itoh et al., 1999).
Normally, Nrf2 binds to the antioxidant response element (ARE) in the promoter region
of genes that code for proteins that are ROS defenses, such as glutathione transferase,
NADPH dehydrogenase, and glucuronsyltransferase (Vomhof-Dekrey & Picklo, 2012).
Understanding how Nrf2 typically works is essential in order to better understand
how its lack of activation would affect the DOX treated cell. Nuclear like factor 2
regularly remains bound by a reducer known as kelch-like ECH-associated protein
(KEAP1). The KEAP1 keeps Nrf2 in the inactive state unless activated by ROS sensitive
cysteine residues. Once these cysteine residues are activated, it causes a conformational
change in KEAP1, resulting in the release of Nrf2. Once free, Nrf2 is free to bind to
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ARE and lead to the transcription of anti-oxidant enzymes (Nordgren & Wallace, 2014).
These systems are often compromised with DOX treatment (Kohen & Nyska, 2002).
Redox cycling plays an important role in normal cellular function, but when this
redox cycling is disturbed, it can cause the activation of a number of proteolytic
pathways, including activation of calpains and caspase 3 (Smuder et al., 2011). Caspase
3 is important because it plays a key role in muscle protein degradation (Du et al., 2004).
It is important to note that caspase 3 can be activated by both intrinsic and extrinsic
pathways, eventually leading to apoptosis (Earnshaw, Martins, & Kaufmann, 1999). The
possibility exists that the rise in mitochondrial oxidative stress and its eventual
dysfunction could be a trigger for the activation of caspase 3 and eventual apoptosis.
Further complicating this issue could be the activation of calpains. Calpains are a class of
proteins that play an important role in proteolysis and cell cycle progression (Kawasaki &
Kawashima, 1996). Activation of calpains is often Ca2+-dependent and they play an
important role in skeletal muscle atrophy (Goll, Thompson, Li, Wei, & Cong, 2003). It
should be noted that when there is a rise in ROS, there is often a rise in Ca2+ (Goll et al.,
2003). The rise in ROS could potentially lead to direct proteolysis via direct oxidative
modification.
Doxorubicin’s toxic effects have usually been attributed to its ROS formation, but
there is some evidence to support the idea that DOX directly interacts with apoptotic cell
signaling (Eom et al., 2005; Zhang, Shi, Li, & Wei, 2009). As mentioned before, DOX
will lead to mitochondrial DNA damage, mitochondrial membrane disruption,
mitochondrial dysfunction, and ATP depletion, which can lead to eventual necrosis and
cell death (Lebrecht & Walker, 2007).
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Previous research has shown that DOX will lead to apoptosis via activation of p53
(X. Liu, Chua, & Gao, 2004), down regulation of GATA-4 (Kim, Ma, & Kitta, 2003),
and degradation of p300 (Poizat, Puri, Bai, & Kedes, 2005). It is important to note that
GATA-4 is an upstream activator of BCL-X. This is a key survival factor for postnatal,
differentiated cardiomyocytes. P300 is an important component of the cell cycle,
differentiation, tumor genesis, and apoptosis (Polich, 1998). In the DOX treated cell, the
activation of p38 kinases alpha and beta actively degrade p300, which can lead to
apoptosis. Evidence also supports the idea DOX can lead to activation of apoptosis via
the antigen 1 (FAS) receptor and its ultimate activation of caspase-8 in the S-type
neuroblastoma (Fluda, Sieverts, Friesen, Herr, & Debatin, 1997). Interestingly, there is
evidence to suggest that DOX may still lead to apoptosis even when caspase-8 has been
silenced, as well as in cells that have been silenced for FAS mediated apoptosis (Shain,
Landowski, Buyuksal, Cantor, & Dalton, 2000). Taken together, it is clear to see that
DOX can be effective at triggering apoptosis even when key signaling elements have
been removed. It has also been proposed that DOX may also exert its effects through the
up-regulation of the E3 upiquitin-ligase atrogin 1/MAFbx, suggesting that atrophy could
be occurring through the proteasome pathway (Yamamoto et al., 2008).
Cardiac Dysfunction
The first report of DOX-induced cardiotoxicity was in 1973. It was characterized
by deterioration of the myocardium assessed through echocardiograms and postmortem
examinations (Lefrak, Pitha, Rosenheim, & Gottlieb, 1973). Later on it was discovered
DOX given at high doses (550mg/m2) was associated with an increased incidence of
heart failure (Swain, Whaley, & Ewer, 2003).
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In human studies, DOX administration has been associated with a decreased
ejection fraction and altered diastolic function (Haq et al., 1985; Swain et al., 2003).
Similarly, animals treated with DOX have reduced left ventricle pressure, reduced
ejection fraction, altered fractional shortening, and increased diastolic pressure (Hayward
& Hydock, 2007; Hydock et al., 2008; Kanter et al., 1985; Singal, Li, Kumar, Danelisen,
& Iliskovic, 2000; Wonders et al., 2008). With higher levels of DOX administration,
there is a corresponding reduction of myocardium around the left ventricle (Chatterjee et
al., 2010; Hayward & Hydock, 2007). The reduction of the myocardium is a major factor
in the development of heart failure and skeletal muscle dysfunction (Hydock et al., 2011).
Several studies have shown the changes resulting from heart failure will
eventually result in reduced blood flow and become a contributing factor in the
development of skeletal muscle dysfunction (Dalla Libera, Vescovo, & Volterrani, 2008;
Harrington et al., 1997; Hydock et al., 2011). Furthermore, the altered cardiovascular
dynamics could also lead to physiological changes within the musculature (Hydock et al.,
2011). Changes in the musculature could include fiber type shifts towards a more
anaerobic type. Yet, there are also other external factors to consider such as the
proclivity of cancer patients to engage in sedentary activities (Inui, 2002) and inadequate
energy consumption (Adamsen et al., 2009), which could further alter skeletal muscle
characteristics. All of these would eventually become compounding variables that would
only serve to enhance fatigue and muscle dysfunction. Together, this demonstrates the
need for understanding DOX-induced muscle dysfunction outside of these compounding
effects.
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Muscle Dysfunction
Physician reports have noted lower extremity muscle weakness in patients
undergoing chemotherapy with DOX (Harada et al., 2004). Functionally, patients
receiving DOX have reduced 12-minute walk distances and increases in reported fatigue
(Gilliam & St Clair, 2011). In animal models, it has been shown that DOX
administration results in a loss of muscle mass, altered myofilament structure, and
depressed force production (McLoon, Luo, & Wirtschafter, 1993). Doxorubicin-induced
muscle dysfunction most commonly manifests itself in the form of reduced maximal
twitch force, reduced rate of force decline and rate of force development, and increased
fatigability (De Beer, Finkle, Voest, Van Heijst, & Schiereck, 1992; Hydock et al., 2011).
Clinical studies have shown that patients receiving DOX often report lower limb
weakness (Jhamb et al., 2007) and a reduced exercise tolerance (Schwartz, 2000).
Furthermore, leukemia patients who received treatment with DOX have exercise
intolerance for one to five years following chemotherapy (Elbl et al., 2006). Moreover,
limb strength is often compromised in patients undergoing treatment with DOX,
providing further evidence of the effects of DOX on skeletal muscle (Galvao, Taaffe,
Spry, Joseph, & Newton, 2010; Galvao et al., 2009). Additionally, patients receiving
isolated limb perfusions of DOX have shown a reduction of size in both type 1 and type 2
fibers (Bonifati et al., 2000). Similarly, patients undergoing chemotherapy with DOX
often display decreased body weight and muscle mass (Tozer et al., 2008). It has also
been shown that the degree of limb atrophy correlates with the DOX concentration within
the quadriceps (Pfeiffer et al., 1997).
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Further complicating the issue is that DOX also exerts a negative effect on the
respiratory muscles. Up to 70% of patients receiving DOX show a depressed maximal
oxygen consumption and premature fatigue during exercise testing (Elbl et al., 2006).
There is further evidence that those receiving DOX also have reduced maximal
inspiratory pressures (Travers et al., 2008). This suggests a compromised diaphragm and
possible dyspnea. Dyspnea is often associated with fatigue during chemotherapy
(Ripamonti, 1999).
Other studies have noted DOX’s myotoxic effects from a therapeutic aspect.
Local DOX injections have been used clinically to treat blepharospasm, hemifacial
spasm, and other related disorders permanently and non-surgically (McLoon, Ekern, &
Wirtschafter, 1992). In a study by Goding and Pernell (2000), clinical use of DOX for
management of spasmodic dysphonia was investigated as a possible long-term treatment.
The authors attempted to use DOX to weaken the canine vocal cord closure without a
notable disruption in the mucosal wave. They found that 3 mg of DOX was capable of
reducing tension by 74% compared to an average side to side difference of 12% in the
control group (Goding & Pernell, 2000).
Another study investigated the use of DOX on rabbit sternocleidomastoid muscle
and found similar results. Rabbits injected with 2 mg/kg of DOX were found to have a
reduced cross-sectional area of 71% versus control animals. Total muscle strength was
50% of controls two months post injection. It is also interesting to note that the DOX
treated sternocleidomastoid muscle had lower force development at all frequencies,
although the lower frequency stimulation failed to produce a significant response
(Falkenberg, Iaizzo, &McLoon, 2001).
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In one of the first studies to examine the direct role of DOX-induced muscle
dysfunction, it was observed that DOX produced an increase in tension that was
dependent on the time and Ca2+ concentrations used (De Beer et al., 1992). The authors
of this study believed the increased tension generated was likely a result of DOX-myosin
ATPase interaction (De Beer et al., 1992). Doxorubicin injected directly into the eyelids
of primates showed myofibrillar dissolution within the orbicularis oculi muscle at five
minutes post injections (McLoon, Luo, &Wirtschafter, 1993). Similar results were found
by McLoon and colleagues (1992) who injected DOX into the eyelids of monkeys with a
combination of 1 mg of DOX and 0.25 mg Verapamil, which led to significant loss in
muscle mass (McLoon et al., 1992). Loss of myofibrillar organization and interstitial
edema has been found following a single injection of DOX (Doroshow et al., 1985).
Further studies have noted that DOX treatment will also result in nucleolar segregation
and altered perinucleolar chromatin distribution (Merski, Daskal, & Busch, 1978; Van
Vleet & Ferrans, 1980). It is clear that DOX has a powerful effect on skeletal muscle, but
the mechanism by which DOX exerts this effect is less clear.
Doxorubicin has been known to interfere with the respiratory chain and inhibit
oxidative phosphorylation (Smuder et al., 2011; van Norren et al., 2009). This distorted
mitochondrial function is believed to increase the formation of ROS and leads to altered
energy availability and altered cellular function. Further complicating the issue is that
when energy stores start to deteriorate, there is often a rise in free intracellular Ca2+
(Honda, Kondo, Zhao, Feril, & Kitagawa, 2004). In a normal cell, the rise in free
intracellular Ca2+ is the result of Ca2+ flowing down its concentration gradients and then is
actively pumped out of the cytosol. In the DOX treated cell, the picture becomes less
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clear because DOX’s possible effect on the SR could be helping to contribute to a
prolonged rise in free intracellular Ca2+ via damage from the generation of ROS or the
direct interference in Ca2+ handling proteins. This idea was best evidenced by an early
study done by De Beer and colleagues (1992) found that there is increased Ca2+
sensitivity in single skinned muscle fibers treated with DOX during low frequency
stimulation, but there was not an increased force production during high frequency
stimulation. Direct incubation with 100-175 µm of DOX for one hour resulted in a time
and contraction dependent decrease in maximal force (van Norren et al., 2009).
Furthermore, in the presence of DOX, maximal force increased during the contraction
phase at lower frequencies (40 Hz) and tended to disappear at higher frequencies (van
Norren et al., 2009). This suggests there is an effect from DOX on the SR, or at least
some effect on the Ca2+ handling that results in a transient Ca2+ increase in the cytosol.
The authors of the previous study suggested the rise in Ca2+ was not a result of DOX
acting directly on the SR itself, but action of DOX affecting Ca2+ reuptake by the SR,
which leads to increased Ca2+ responses and prolonged relaxation times.
Doxorubicin at a low dose of 1.15 mg/kg leads to a reduction in force production
in both type 1 and type 2 muscles (Ertunc, Sara, Korkusuz, & Onur, 2009). The authors
of this study believed the loss of force was the result of a reduction in the muscle-specific
isoform of the sarco/endoplasmic reticulum ATPase (SERCA). This loss of the musclespecific isoform of SERCA could also help to explain the rise in free intracellular Ca2+.
There is consensus that DOX has the ability to interfere with the contractile
properties of skeletal muscle, but the exact mechanism by which this occurs is still
elusive. The most plausible explanation behind this dysfunction is that it is the result of
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two distinct properties. First, the SR dysfunction is the result of oxidative damage to the
lipid membranes and the oxidation of Ca2+ handling proteins. Second, the damage that
occurs to the mitochondria via the excessive generation of free radicals leads to a reduced
adenosine triphosphate (ATP) supply and reduced energy availability for cellular
functions. If these two possible modes of dysfunction are correct, it could be possible to
alter the toxic effects of DOX with interventions that have the ability to enhance ATP
supply and preserve function.
Exercise and Doxorubicin
Doxorubicin is a powerful chemotherapy agent with potent anticancer properties.
Because DOX’s use is limited by the development of its side effects (Chatterjee et al.,
2010), any treatment that mitigates the progression of these side effects should receive
increased attention. If these side effects can be mitigated, the amount of DOX given
during chemotherapy treatment could be increased, it could improve the patient’s quality
of life, and increase the survivability of treatment with DOX. One of the most successful
methods to mitigate the side effects of DOX is with exercise.
Studies examining the role of aerobic exercise prior to DOX treatment found that
trained animals typically have a higher end systolic pressure, left ventricular developed
pressure, and maximal rate of left ventricular pressure development (Chicco et al., 2005;
Hydock et al., 2008; Wonders et al., 2008). Low intensity exercise training prior to and
during treatment was also shown to preserve cardiac function (Chicco et al., 2005, 2006).
There is also evidence that a single bout of exercise at 25 m/min for 60 min prior to DOX
treatment with 15 mg/kg, resulted in a cardio protective effect with preserved end systolic
pressure and maximal developed left ventricle pressure (Wonders et al., 2008). Aerobic
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exercise can also lead to the attenuation of the DOX-induced mitochondrial dysfunction
at complexes I and V, decreased caspase 3 and 9 activities, and increased cardiac
mitochondrial SOD activity (Ascensao et al., 2011). Furthermore, chronic exercise
training has been beneficial in the protection of DOX-induced vascular dysfunction. Rats
that engaged in voluntary wheel running for 14 weeks had significantly greater smooth
muscle contractile force and improved endothelium-independent relaxation times 24
hours after a single DOX dose of 15 mg/kg (Gibson, Greufe, Hydock, & Hayward, 2013).
In order to maintain homeostasis, it is critical that the body be able to correctly
manage its antioxidant status. This suggests that there is balance between the production
of ROS and the ability of the cell to quench these through its antioxidant defenses.
Exercise has been shown to increase superoxide dismutase 1 (SOD1), superoxide
dismutase 2 (SOD2), and glutathione peroxidase (GPX) levels in skeletal muscle (Ji,
2008). As mentioned earlier, DOX is a powerful chemotherapy agent that can greatly
increase the oxidative state of the cell. This rise in the ROS is troublesome to noncancerous tissues and is likely a contributing mechanism to the cardiotoxicity,
myotoxicity, and fatigue commonly seen with DOX treatment. Although there is little
doubt that aerobic exercise has a potent effect on mitigating DOX-induced cardiotoxicity,
there has been no investigation on the ability of exercise to offset DOX-induced muscle
dysfunction.
There is growing evidence that exercise can be effective at minimizing cancer
related fatigue and improving quality of life (Quist et al., 2006; Spence, Heesch, &
Brown, 2010). Empirical evidence does overwhelmingly suggest that exercise, in
general, is a safe and effective during the administration of adjuvant cancer therapies
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(Cheema, Gaul, Lane, & Fiatarone Singh, 2008; Jones & Demark-Wahnefried, 2006;
McNeely et al., 2006). However, the appropriate modalities and dosages required to
produce these positive effects have yet to be fully elucidated. Even with the prevailing
focus upon the effectiveness of aerobic exercise, there is a growing body of data for the
benefits of other forms of exercise (Focht et al., 2013). For example, resistance training
(RT) produces a number of beneficial adaptations that could be effective at minimizing
the clinically relevant physiological (muscle mass, strength, bone density, and body
composition) and quality of life outcomes in cancer patients and survivors.
In humans, RT has the capability to produce a wide range of adaptations such as
improved muscular performance, increased rates of hypertrophy, improved body
composition, increased appetite, and increased bone strength (Winett & Carpinelli, 2001).
Furthermore, RT has been used as a means of palliative care and has been shown to
reduce cancer-related fatigue (Adamsen et al., 2009; Meneses-Echavez, GonzalezJimenez, & Ramirez-Velez, 2014), improve muscular strength in patients with heart
failure (Gielen, Laughlin, O'Conner, & Duncker, 2014), preserve muscle mass in patients
with heart failure (Gielen et al., 2014), promote increased blood cell counts in those
going through chemotherapy (Karvinen, Esposito, Raedeke, Vick, & Walker, 2014), and
improve breast cancer outcomes during chemotherapy (Courneya et al., 2014). These
demonstrate the benefits from RT stand in sharp contrast to myotoxicity seen with DOX.
Thus, it can be concluded that RT could be used to minimize DOX-induced muscle
dysfunction.
At the cellular level, RT produces a number of favorable adaptations, which could
be used to offset the myotoxic effects of DOX. Resistance training results in the
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activation of protein kinase B (Akt), mammalian target of rapmacyacin (mTOR), and
mitogen-activated protein kinase (MAPK) signaling pathways (Bodine et al., 2001). The
activation of these cellular pathways can lead to the downstream activation of the
ribosomal protein S6K (p70 S6K) (Terada et al., 1994). The activation of p70 S6K
ultimately results in an increase in protein synthesis and an increase in muscle size
(Spiering et al., 2008). In addition, AKT can also phosphorylate the fox-head box O
(FOXO) family of transcription factors, which can prevent FOXO from stimulating the
transcription of some proteolytic ubiquitin ligases (Sartorelli & Fulco, 2004).
Furthermore, RT can also increase circulating concentrations of insulin like growth factor
1(IGF-1) and growth hormone (Spiering et al., 2008). Elevations in both of these
hormones help to improve the likelihood for an increase in protein synthesis and overall
muscle size. Furthermore, a greater muscle size could increase the capacity of cancer
patients to perform ADLs and improve their overall quality of life.
Resistance training has been shown to be beneficial for minimizing fatigue and
improving quality of life in cancer patients (Courneya & Friedenreich, 1999). However,
there is substantially less information about the appropriate dosages for the application of
RT. It is important that further studies be done to identify the appropriate application of
RT, and in a manner that is clinical relevant to cancer patients
Current evidence suggests that a RT period from six weeks to six months is
required to minimize the side effects of the cancer treatment process. The inclusion of
RT produces meaningful improvements in a wide variety of physiological and quality of
life outcomes during the cancer treatment process. However, there is a great deal of
variability in the improvements seen with RT (Focht et al., 2013). In general, evidence
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does suggest that RT will produce a statistically significant increase in muscular strength,
muscular endurance, improvements in physical function, and some improvements in
quality of life (Howlader et al., 2013; Speck, Courneya, Masse, Duval, & Schmitz, 2010).
It is difficult to extrapolate the findings of clinical studies to general cancer rehabilitation
recommendations because of the different cancer types, the kinds of treatment, and
treatment stage at which the RT was implicated. As a result, it can be hard to generalize
the findings of these studies to larger populations. Animal-based studies, on the other
hand, can provide an alternative to the compounding variables commonly seen with
clinical type studies. By utilizing these types of studies, scientists can develop treatment
recommendations based on the treatment type and level.
Most studies involving small animals generally report that RT produces a similar
set of adaptations to that of humans (Cholewa et al., 2014). In response to RT, both
humans and small animals show an increase in hypertrophy, improvements in skeletal
muscle strength, and an increase in protein synthesis (Cholewa et al., 2014).
Furthermore, studies involving animals allow for the researchers to standardized the
treatment, and reduce the overall variability of the study. In addition, it lets researchers
study RT in a setting away from the secondary disease process (e.g., heart failure,
cachexia, inadequate energy consumption) that take place in some cancer patients.
Most animal studies use a weighted vest, tail weights, weighted ladder climbing,
or weighted swimming to simulate anaerobic exercise (Cholewa et al., 2014). However,
there is little carryover from these investigations that can be translated into future clinical
recommendations. A secondary concern from these types of investigations is the level of
distress experienced by the animal. The experienced distress could become a
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compounding variable in the interpretation of the results of these studies. Thus, it would
be advisable to incorporate a model in which animal distress is minimized, is clinically
relevant, and produces a meaningful and reproducible effect.
In comparison to aerobic training, there is considerably less evidence regarding
the benefits of RT on minimizing the side effects of chemotherapy. However, the
available data suggested RT represents an exercise intervention that may produce a wide
range of health benefits during the cancer treatment process (Antonelli, Freedland, &
Jones, 2009; Courneya, 2009; Courneya & Friedenreich, 2001; Focht et al., 2013). From
this, we can conclude that exercise not only has the potential to minimize the myotoxic
effects of DOX but could also help minimize its effects on other bodily systems. To date,
there have been no investigations on the ability of prior RT to minimize DOX-induced
skeletal muscle dysfunction.
Creatine
Creatine is a natural occurring substance that is typically supplied through the diet
and is located throughout the body, with the vast majority of it being stored in skeletal
muscle (Walker, 1979). The use of supplemental Cr can be traced back to the early 20th
century when Harvard researchers first discovered that ingesting Cr produced an increase
in intramuscular Cr stores (Folin & Denis, 1912). A few years later, scientists started to
understand the ability of phosphocreatine (PCr) to donate a phosphate to adenosine
diphosphate (ADP) and produce ATP (Fiske & Subbarow, 1927). The use of
supplementary Cr as an ergogenic aid has become increasingly popular since the early
1990s (Demant & Rhodes, 1999). Supplementation with exogenous Cr can produce a
wide range of benefits including preventing reductions in PCr, increased fiber size,
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increases in total lean body mass, and increased rates of protein synthesis (Persky &
Brazeau, 2001). It has also been shown that Cr can provide powerful performanceenhancing effects in the form of increased force production, reduced fatigue, and
increased muscle mass (Persky & Brazeau, 2001). The benefits of Cr could therefore
provide a means of overcoming DOX-induced muscle dysfunction.
Creatine is a naturally occurring compound obtained from endogenous production
and dietary intake (Persky & Brazeau, 2001). The synthesis of Cr is the product of 3 key
amino acids: arginine, methionine, and glycine. The primary reaction in the formation of
Cr is the formation of guanidinoacetate. In this reaction, the compounds glycine and
arginine are catalyzed by the kidney enzyme arginine glycine amino transferase (AGAT)
(Wyss & Kaddurah-Daouk, 2000). This primary reaction is considered to be the ratelimiting step in the formation of Cr. The second reaction takes place in the liver and is
the methylation of guanidinoacetate, which produces Cr. The process of methylation
involves the donation of the methyl group from methionine via the enzyme
guanidinoacetate N-methyltransferase (GAMT; Persky & Brazeau, 2001; Wyss &
Kaddurah-Daouk, 2000). Once Cr reaches a particular level, it acts as a negative
feedback mechanism, which is able to inhibit AGAT mRNA (Wyss & Kaddurah-Daouk,
2000).
Once produced, Cr is transported throughout the body by the blood stream where
it is taken up by working tissues via a sodium- and chloride-dependent transporter
(CreaT; Guerrero-Ontiveros & Wallimann, 1998). The CreaT transporter is expressed in
a variety of tissues including kidney, heart, skeletal muscle, brain, testis, and colon, but
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not in the liver, pancreas or intestine (Guimbal & Kilimann, 1993; Nash et al., 1994; Sora
et al., 1994).
In the muscle cell, total Cr content is dependent on fiber types, catecholamines,
IGF-1, insulin, and exercise (Persky & Brazeau, 2001); however, the most important
factor regarding total Cr content is probably the fiber type itself. In the rat, type 1 fibers
from the soleus show total concentrations of Cr at 23±1 µmol/gww, whereas type 2 fibers
from the EDL show concentrations of 35±1 µmol/gww of Cr (Kushmerick, Moerland, &
Wiseman, 1992; Willott et al., 1999). In human skeletal muscle, Cr levels can range from
110 to 160 mmol/kg (Bemben & Lamont, 2005; Harris, Hultman, & Nordesjo, 1974).
Upon entering the cell, Cr provides a number of protective and energy-sparing
effects that are likely responsible for its improvements in muscle function. The primary
benefits from Cr are its energy-preserving effects, its effects on protein synthesis, and its
ability to facilitate membrane stabilization (Persky & Brazeau, 2001).
Adenosine triphosphate (ATP) is the energy currency for most biological systems
in the human body (Lehninger, 1982). Excitable cells and tissues depend on large
amounts of ATP that are used in a fluctuating manner, and maintaining this supply of
energy is of critical importance. In addition, many key cellular functions are regulated by
ATP, ADP and AMP, as well as the ATP/ADP ratio (Tornroth-Horsefield & Neutze,
2008). Given that most cells only contain a small amount of freely available ATP (2-5
mM) (Beis & Newsholme, 1975), which could only provide a few seconds of ATP, a
system needs to be in place to rapidly provide the cell with the needed energy when the
time arises. To facilitate this transient and localized energy demand, Cr and PCr are in
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rapid exchange because of the process of trans-phosphorylation via creatine kinase (CK;
Harris, Soderlund, & Hultman, 1992).
Creatine kinase works by transferring the phosphate group of ATP to Cr. This
reaction results in the formation PCr. The stored inorganic phosphate can be utilized for
the immediate ATP generation in periods of acute need. Phosphocreatine is unique
because it protects the cell from a reduction in energy supply and acts as a pH buffer
(Persky&Brazeau, 2001). The energy-sparing effects of PCr come from its ability to
preserve ATP availability and prevent the excessive buildup of ADP, which could alter
the rate of energy-dependent actions like cross bridge cycling. It should be mentioned
that there are two key CK enzymes--one that functions within the cytosol and one that
functions within the mitochondria (Clark, 1997).
The mitochondrial CK is found within the mitochondrial intermembrane space,
where it works to produce PCr from mitochondrial generated ATP and imported Cr from
the cytosol (Schlattner, Tokarska-Schlattner, & Wallimann, 2006). Together, both the
cytosolic and mitochondrial CKs work together in an ATP dependent process known as
PCr/Cr shuttle. This system involves the shuttling of mitochondrial produced PCr by
mitochondrial CK to cytosolic CK. Once accepted, the PCr can be used to generate ATP.
This suggests PCr is not only acting as an energy buffer, but also as a cellular energy
transporter from areas of energy production to areas of energy utilization (Schlattner et
al., 2006).
Exercise and Creatine
Well over 500 research studies have evaluated the effects of Cr supplementation
on muscle physiology and/or exercise capacity in healthy, trained, and various diseased
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populations (Kreider, 2003). A number of studies have analyzed the effects of Cr with
RT or other short-term activities such as sprint performance; however, early data were
not conclusive, with some reporting no measurable benefit and others reporting marked
improvements with Cr. A review by Rawson and Volek (2003) found Cr
supplementation with RT generally produced an 8% greater increase in muscular strength
when compared to resistance training alone.
Another review found that nearly 70% of studies examining the effects of Cr
supplementation found noticeable improvements in high-intensity performance with Cr
supplementation while the other 30% showed no effect. It was reported that short-term
supplementation with Cr was able to improve maximal strength by 5-15% (Kreider,
2003). Although most cancer patients do not engage in regular physical activity, they do
need to perform ADLs. The nature of ADLs is quite similar to that of RT. Both RT and
ADLs usually involve short bursts of activity and rely heavily on Cr/PCr system. If the
same benefits can be attained in the DOX treated muscle, it is possible to offset DOX’s
myotoxic effects with the combination of RT and Cr supplementation. If true, this could
provide the cancer patient with increased capacity to perform ADLs, improve muscular
endurance, and minimize fatigue. Despite the fact that not all studies have found
significant improvements in performance, the great preponderance of gathered evidence
does suggest Cr is an effective nutritional ergogenic aid for a variety of exercises and
possibly for clinical populations.
Exercise intolerance is a major limiting symptom in patients receiving
chemotherapy (Jones et al., 2011). Part of this fatigue is attributable to chemotherapyinduced cardiotoxicity and the systemic effects of a reduced blood supply. Exercises that
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improve hemodynamics and left ventricle function do not improve exercise capacity
immediately when blood flow is increased (Wilson, Martin, & Ferraro, 1984; Wilson,
Martin, Ferraro, & Weber, 1983). If short-term energy supplies can be increased, it
might be possible to minimize this exercise intolerance until energy production from
glycolytic and oxidative sources can catch up.
Studies that use phosphorus-31 nuclear magnetic resonance have shown significant
reductions in PCr levels in patients with heart failure (Massie et al., 1988). In the DOX
treated heart, there is a similar reduction of intracellular Cr and ATP (Pelikan et al.,
1986). However, intracellular levels of Cr and ATP have not been examined in the DOX
treated muscle. Given Cr’s multifaceted role in energy maintenance, it could be plausible
that changes in cellular metabolism resulting from alterations in the levels of Cr and PCr
in skeletal muscle could be contributing to the development of exercise intolerance and
excessive fatigue. If this reduction in intracellular Cr could be minimized, it might be
possible to attenuate some of the negative changes in muscle metabolism during DOX
treatment.
The use of RT and supplementary Cr could be a possible treatment to help
minimize DOX-induced muscle dysfunction. Interestingly, heavy exercise has been
shown to improve PCr resynthesis after exercise (Arnold, Matthews, & Radda, 1984).
With the appropriate application of RT, it may be possible to facilitate Cr uptake in the
DOX-treated muscle. If intracellular Cr can be increased, it could enhance short-term
ATP supply, improve muscle function, and minimize fatigue.
Supplementation with Cr generally produces an increase in intracellular Cr during
the initial loading phase, but as intracellular CR rises, it begins to reduce CreaT
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expression and slow Cr uptake (Snow & Murphy, 2001). However, supplementary Cr
will produce an overall increase in the rate of PCr resynthesis and total Cr (Greenhaff,
Bodin, Soderlund, & Hultman, 1994). Interestingly, supplementation with Cr does
enhance muscle PCr resynthesis during the second minute of recovery from intense
muscular contraction (Greenhaff et al., 1994). Furthermore, elevated pre-exercise muscle
PCr levels generated by Cr loading have been shown to be maintained during dynamic
intermittent muscle contractions (Vandenberghe, Van Hecke, Van Leemputte, Vanstapel,
& Hespel, 1999). Thus, it can be concluded that RT could enhance Cr uptake and help to
preserve muscle function.
Taken together, the benefits of combined treatment with RT and Cr could
improve muscle function and minimize fatigue, lessen the changes in cellular
metabolism, increase intracellular Cr stores, and improve overall functional capacity.
Each of these benefits could help alleviate some the deleterious side effects of treatment
with DOX and provide cancer patients with a better quality of life and an increased
capacity to perform ADLs.
Creatine and Doxorubicin
Doxorubicin is a common and well-studied chemotherapy agent that comes with a
number of side effects that can lead to a reduction in skeletal muscle function via a
variety of mechanisms, whereas Cr can improve skeletal muscle function and enhance the
PCr system. Taken together, the possibility exists that pretreatment with Cr might
mitigate some of the myotoxic effects of DOX. To date, few studies exist examining the
role of supplementation with Cr on DOX-induced muscle dysfunction.
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Deficits in energy metabolism are believed to be one of the mechanisms that lead
to DOX-induced cardiotoxicity. Although the exact mechanisms behind DOX-induced
alterations in cardiac energy metabolism have yet to be fully understood, it has been
shown that DOX causes a decrease in high-energy phosphates and a reduction in the ratio
of PCr to ATP (Darrabie et al., 2012; Maslov et al., 2010; Ohhara, Kanaide, &
Nakamura, 1981; Seraydarian, Artaza, & Goodman, 1977). This suggests that as the
cardiomyocytes begin to rely on more anaerobic sources of energy, they lose the ability
to properly couple mitochondrially produced ATP to the recycling of PCr and ADP.
Furthermore, it has also been noted that DOX can lower levels of Cr and CK in cardiac
myocytes (Tokarska-Schlattner, Zaugg, Zuppinger, Wallimann, & Schlattner, 2006).
Additionally, DOX has been shown to reduce Cr transport, decrease Vmax, lower Km, and
reduce the amount of CreaT present at the cell surface in cultured cardiomyocytes
(Santacruz et al., 2014). Although this research was conducted on cardiomyocytes, it
does provide some help in explaining the DOX-induced muscle dysfunction from an
energy standpoint. The possibility of a reduction of ATP and a reduced PCr and ATP
ratio could help explain the prolonged rise in Ca2+ in DOX treated muscle cells. Because
of the reduced ATP availability, there is lack of energy to facilitate the movement of Ca2+
against its concentration gradient, thus leading to an altered cross bridge formation and
compromised skeletal muscle function.
Despite Cr’s notable benefit to the PCr system, there has been little investigation
as to its ability to minimize DOX’s cytotoxic effects. Cultured cardiomyocytes treated
with a 5 nmol/L solution of Cr have shown reduced rates of apoptosis and lower levels of
ROS production following DOX treatment when compared to non Cr treated controls
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(Santacruz et al., 2014). Rats treated with 2 mg/kg of Cr per day for 30 days prior to a 15
mg/kg IP injection of DOX were found to have lower levels of serum lactate
dehydrogenase and creatinine levels compared to DOX-treated controls (Santos, Batista,
Caperuto, & Costa Rosa, 2007). These results demonstrate that there is some capacity for
Cr to mitigate the toxic effects of DOX.
To date, no study has been conducted to assess the ability of Cr to mitigate
myotoxic effects of DOX. A pilot study using 10-week-old male Sprague-Dawley rats
was conducted on the feasibility of Cr to mitigate the myotoxic effects of DOX. In this
study, excised SOL and EDL muscles were treated with either a Krebs-Henseleit buffer
(K) or K containing 25 mM of Cr. Tissues were then treated with K or K containing 24
μM of DOX. The results for this pilot study indicated Cr pretreatment protected against
DOX-induced muscle fatigue in the SOL (see Appendix A). Additionally, a trend did
show some Cr-induced protection against DOX-dysfunction in the EDL. This pilot
suggested Cr exerted a protective effect on skeletal muscle.
Summary
Doxorubicin-induced muscle dysfunction most commonly manifests itself in the
form of reduced maximal twitch force, reduced rate of force decline and force
development, and increased fatigue ability (De Beer et al., 1992; Hydock et al., 2008,
2011; van Norren et al., 2009). Creatine is unique in the fact that it is a well-studied
ergogenic substance with documented effects on improving human performance (Persky
& Brazeau, 2001). Typically, these benefits are the result of the enhancement of Cr/Pcr
system and Cr-Pcr shuttle. The cardiotoxic side effects of DOX have been shown to be
attenuated by aerobic exercise (Hydock et al., 2008; Kanter et al., 1985; Wonders et al.,
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2008). Yet, there has been little investigation into the ability of RT to attenuate DOXinduced muscle dysfunction. Thus, the current study examined the combined effects of
RT and Cr on DOX-induced myotoxicity.

CHAPTER III

METHODS

Doxorubicin (DOX) is well known for its anti-cancer effects, but it can cause
severe disruptions in skeletal muscle function. The mechanisms behind this dysfunction
have yet to be fully explained but likely result from a combination of excess levels of
ROS and interference in energy availability. Given the proposed mechanisms behind
DOX-induced muscle dysfunction, Cr and RT, individually, could each offer a reprieve
from the harmful effects of DOX. In combination, they have the possibility of providing
substantial protection against DOX-induced muscle dysfunction. This chapter describes
the methodology used to examine the effects of Cr and RT on DOX-induced muscle
dysfunction.
Animals and Animal Care
All procedures were approved by the University of Northern Colorado’s
Institutional Animal Care and Use Committee (IACUC; see Appendix B). Ten week-old
male Sprague-Dawley rats (N = 64), weighing approximately 300 grams, were used in
this study. Animals were housed two per cage in standard 20.32 cm high and 26.67 cm
wide by 48.26 cm deep plastic rat cages and were put on a 12hr/12hr light/dark cycle in a
temperature and humidity controlled environment. Animals had access to standard chow
and distilled water ad libitum for the duration of the study.
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Training Protocol
Animals were randomly assigned to either a RT group (n = 32) or sedentary
(SED) group (n = 32) for six weeks. A six week RT training protocol was used because
it represented the minimal amount of time required to reduce fatigue, improve muscular
strength, and increase physical and functional activity in cancer patients undergoing
chemotherapy (Adamsen et al., 2009). At the end the end of training period, animals
were further divided into four groups (n = 16) based on the first treatment buffer (Cr or
K). Animals were then further divided into eight groups (n = 10) based on the second
treatment buffer (DOX or K). An illustration of the experimental design can be seen in
Figure 3.1.
Resistance training was simulated by placing rats in cages where the food and
water were progressively elevated over the course of two weeks until reaching a final
height of 0.2 meters above normal (see Figure 3.2). Animals remained in the elevated
food and water cages for four weeks. This elevated height caused the rats to rise to a
bipedal stance or jump to reach their food and water, thus providing a representative
model for chronic hind limb loading and RT. This model has been shown to increase
hypertrophy of the hind limb muscles and increase hind limb bone density while
minimizing animal distress (Yao, Jee, Chen, Li, & Frost, 2001). Animals were kept in
the elevated food cages for a total of 6 weeks. Animals assigned to the SED group were
kept in standard cages for an equivalent amount of time.
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Figure 3.1. Illustration of experimental design. Abbreviations: RT- Resistance
Training; SED- Sedentary; Cr- Creatine Monohydrate; Krebs- Krebs-Henseleit
Buffer.

Figure 3.2. Photographs of standard rat housing (left) and an elevated food cage
(right). The elevated housing causes the rat to rise to a bipedal stance, which
provides a representative model for resistance training.

40
Skeletal Muscle Function
After six weeks of RT or sedentary conditions, each animal was anesthetized with
an intraperitoneal injection of heparinized sodium pentobarbital (50 mg/kg).
Supplemental sodium pentobarbital injections were given as needed. When the animal
was anesthetized, and a tail pinch reflex was absent, the right and left SOL and EDL were
quickly excised and placed in oxygenated (95% O2 and 5%CO2) Krebs Henseleit buffer
(K) (120 mM NaCl, 5.9 mM KCl, 2.5 mM CaCl2, 1.2 mM MgCl, 25 mM NaHCO3, 17
mM glucose, pH 7.4) heated to 36.8°C. Excised tissues were given two minutes to
recover from surgery, and then the muscle was mounted in an ex vivo muscle function
apparatus (see Figure 3.3). The proximal end was attached to a spring clip connected to a
force transducer. The distal end was attached to a stationary glass hook. Stimulation of
excised muscles was initiated with field stimulating electrodes. Maximal twitch
characteristics (maximal twitch force, maximal rate of force development, and maximal
rate of force decline) were recorded through ADInstruments Lab Chart software
(Colorado Springs, CO).
Functional data were only collected from the SOL and EDL from the right hind
limb. The muscles from left hind limb of non-DOX treated animals underwent the same
treatment process as the right-sided muscle but without any functional testing.
Following the recovery period and prior to the first incubation, optimal maximal
twitch characteristics were determined and recorded for the muscles of the right hind
limb. A baseline tension of 0.5 grams was applied to the muscle and twitch force was
measured. Tension was increased by 0.2 grams until an increase in twitch force was no
longer present. The muscle was given a two minute recovery period after each
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stimulation. Next, optimal voltage was determined using a similar process of increasing
voltage from a baseline of 40 volts by 10 volts until an increase in contraction strength
was no longer evident. The muscle was again given a two minute recovery period after
each stimulation. When these settings were identified, the buffers were changed to the
first treatment buffer for both sets of muscles.

Figure 3.3. Schematic of ex vivo muscle function apparatus.

The first treatment buffer was either a K buffer or K buffer containing Cr (25
mM). During the incubation period, the muscle was stimulated at 100 Hz for 200 msec
every five minutes using the same established twitch settings. This stimulation protocol
has been previously shown to facilitate movement and activation of the Cr transporter
(CreaT) (Head et al., 2011). Following the 30 minute incubation period, the buffer was
changed to the second treatment buffer (K or K buffer with DOX [24 µM]), and both sets
of muscles were allowed to incubate for another 30 minutes. A DOX concentration of 24
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µM was used because it best represented the upper limits for serum concentrations
immediately following infusion with DOX (Baurain, Deprez-De Campeneere,
Zenebergh, & Trouet, 1982). The muscles were stimulated for 200 msec at 100 Hz once
every five minutes for the duration of second incubation using the same voltage as
before.
At the end of the final incubation, left hind limb muscles were removed from the
tissue bath, weighed, frozen in liquid nitrogen, and stored in in -80°C for later
biochemical analysis.
The buffers were replaced again with fresh K buffer and then muscle
characteristics were reassessed using the initial maximal twitch settings. Following
maximal twitch determination, the tissues were supplied with fresh K and analyzed for
fatigue. Fatigue rate was determined using the same voltage settings from maximal
twitch determination with a frequency of 83 Hz and pulse duration of 500 ms (square
wave pulses). Muscles were stimulated to contract every second for 100 seconds and
twitch forces through the course of the protocol were recorded. At the end of data
collection, tissues from the right limb were weighed, frozen in liquid nitrogen, and stored
in -80°C for biochemical analysis.
Creatine Content Analysis
A 1:4 weight/volume ratio of Cr assay buffer (Sigma-Aldrich, St. Louis, MO) and
5 μL of protease inhibitor (Sigma-Aldrich, St. Louis, MO) were added into an Eppendorf
tube along with a portion of tissue and homogenized using a Dounce homogenizer. After
five minutes of homogenization, a sonicator (Fisher Scientific model 100 sonic
dismembrator; Waltham, MA) was used to further disrupt cell and organelle membranes
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at 1-second pulses, repeated five times. After five minutes of homogenization, the
homogenates were centrifuged through a 10 Kda micro spin filter (GE28-9322-47,
Sigma-Aldrich, St. Louis, MO) at 10,000 g for 10 minutes at 4℃. After centrifugation,
the supernatant was collected and transferred to a new Eppendorf tube. Total protein
concentration of the sample was determined using the Bradford protein assay method
(Bradford, 1976).
Analysis of total creatine content was done using the Sigma-Aldrich creatine
assay kit (MAK079, Sigma-Aldrich, St. Louis, MO). Standards were prepared by mixing
10 µl of reconstituted creatine standard with 990 µl of assay buffer to generate a 1mM
(nmole/µl) standard solution of working solution. Amounts of 0, 2, 4, 6, 8, and 10 μL of
the 1 mM creatine standard solution were loaded onto a 96 well plate, generating 0
(blank), 2, 4, 6, 8, and 10 nmole/well standards. Next, the reaction mix was prepared by
adding 44 µl of creatine assay buffer, 2 µl of creatinase, and 2 µl creatine enzyme mix, 2
µl of creatine probe. 50 µl of reaction mix was added to each sample and standard; each
was allowed to incubate at 37°C for one hour. The standards were analyzed at 570 nm to
develop a standard curve. Samples were then analyzed at 570 nm to determine total Cr
content using the standard curve.
Statistical Analysis
All data were presented as mean ± standard deviation (mean ± SD). A threefactor analysis of variance (ANOVA) was used to determine main effects and interactions
for the three treatments (RT, Cr, and DOX). Tukey’s post-hoc analysis was used to
determine significance between treatment combinations on maximal twitch
characteristics. The dependent variables for maximal twitch characteristics were
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maximal twitch force, maximal rate of force development, and maximal rate of force
decline. A two-way ANOVA was used to determine the effects of RT and Cr on
intracellular Cr content. Tukey’s post-hoc analysis was used to determine significance
between the groups. The dependent variable for Cr content was the calculated Cr
concentration. Fatigue was analyzed over time using repeated measures ANOVA with a
Dunnett’s post-hoc analysis. A significance level of α = 0.05 was used for all statistical
analyses. Graph Pad Prism (San Diego, CA) and Statistical Analysis System (Cary, NC)
were used for statistical analysis.

CHAPTER IV

RESULTS

Doxorubicin (DOX) is a powerful chemotherapy agent with potent anticancer
properties, but it can cause severe disruptions in normal skeletal muscle function. The
specific mechanisms behind this dysfunction have yet to be fully explained; however,
they are likely the result of a combination of excess levels of ROS and interference in
ATP availability. Thus, it might be possible to minimize the DOX-induced muscle
dysfunction with either Cr or RT. Individually, each of these could offer a reprieve from
the harmful effects of DOX. In combination, they have the possibility of providing
substantial protection against DOX-induced muscle dysfunction.
General Observations
Prior to incubation, each animal was weighed and body mass recorded. An
unpaired t-test was performed to determine if the body and tissue masses were
significantly different. Resistance training (RT) animals had a significantly higher body
mass of 393 ± 31 grams when compared to the body mass of 350 ± 29 grams in the SED,
p <0.0001. Furthermore, RT animals had a significantly higher SOL mass when then
those in the SED group, p <0.0001. No significant differences were found EDL mass.
Muscle weights can be seen in Table 4.1.
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Table 4.1
Muscle Masses
Group

L-SOL (g)

L-EDL (g)

Sedentary

0.2109±0.01

0.1975±0.03

Resistance Training

0.2496±0.07

0.2227±0.04

Maximal Twitch Characteristics
Following the incubation periods, maximal twitch characteristics (maximal twitch
force, maximal rate of force development, and maximal rate of force decline) were
assessed and recorded. The selected maximal twitch variables can be seen in Figures 4.14.6. A three-way ANOVA was performed to assess the main effects and interactions of
activity (RT or SED), drug (DOX or K), and nutrition (Cr or K) on each maximal twitch
characteristic in the SOL and EDL. As Figure 4.1 shows, no significant drug effect
existed for SOL maximal twitch force, F(1, 70) = 0.08, p = 0.7744. Likewise, nutrition
had no significant effect on SOL maximal twitch, F(1, 70) = 0.37, p = 0.5437; however,
there was a significant activity effect, F(1, 70) = 5.83, p =0.0184. In general, SED
animals had a higher SOL max twitch than RT animals. Furthermore, a trend toward an
interaction of drug and activity was found on SOL maximal twitch force, F(1, 70) = 3.47,
p = 0.0667. No significant interactions existed between activity and nutrition, F(1, 70) =
0.10, p =0.7524 or nutrition and drug, F(1, 70) = 0.53, p = 0.698. There was also no
statistically significant three-way interaction among activity, drug, and nutrition, F(1, 70)
= 0.37, p =0.05430. To examine the significant effects further, Tukey’s multiple
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comparison tests were performed and no significant differences between the groups were
observed (see Figure 4.2, p > 0.05).
When examining SOL maximal rate force development, no significant main
effects from activity, F(1, 69) = 0.10, p = 0.7482; drug, F(1, 69) = 0.15, p = 0.6966; or
nutrition, F(1, 69) = 0.05, p =0.8265, were found (see Figure 5). In addition, no
significant interactions were observed between activity and drug, F(1, 69) = 0.03, p =
0.8536; activity and nutrition, F(1, 69) = 0.00, p = 0.9713; or nutrition and drug, F(1, 69)
= 2.31, p = 0.1329. Furthermore, no significant three-way interaction existed among
activity, drug, and nutrition, F(1, 69) = 0.67, p = 0.4163.
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Figure 4.1. Soleus maximal twitch force. SED, sedentary; RT, resistance training; K,
Krebs-Henseleit buffer; Cr, Creatine; DOX, doxorubicin. Significant activity effect, F(1,
70) = 5.83, p = 0.0184.

Figure 4.2. Soleus maximal rate of force development. SED, sedentary; RT, resistance
training; K, Krebs-Henseleit buffer; Cr, Creatine; DOX, doxorubicin. No main effects or
interactions.
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Similarly, as illustrated in Figure 4.3, no significant main effects for activity, F(1,
69) = 0.08, p = 0.7846; drug, F(1, 69) = 0.06, p = 0.7689; or nutrition, F(1, 69) = 0.00, p
= 0.9559, were observed for SOL maximal rate of force decline. Likewise, no significant
interactions from either activity and drug, F(1, 69) = 0.00, p = 0.9510; activity and
nutrition, F(1, 69) = 0.03, p = 0.8542; or nutrition and drug, F(1, 69) = 1.54, p = 0.2182,
were observed on SOL maximal rate of force decline. Finally, no significant three-way
interaction was observed among activity, drug, and nutrition, F(1, 69) = 0.42, p = 0.5178,
on SOL maximal rate of force decline.
In the EDL, no significant main effects from the drug existed on EDL maximal
twitch force, F(1, 68) = 0.02, p = 0.8865. Similarly, no significant main effects were
detected with either the activity, F(1, 68) = 0.0, p = 0.9609; or drug, F(1, 68) = 0.02, p =
0.8865 on EDL maximal twitch force (see Figure 4.4). In addition, no interactions were
observed between activity and drug, F(1, 68) = 1.17, p = 0.2839; activity and nutrition,
F(1, 68) = 0.28, p = 0.5999, or drug and nutrition F(1, 68) = 0.30, p = 0.5837 on EDL
maximal twitch force. No significant three way interaction among activity, drug, or
nutrition was detected, F(1, 68) = 0.74, p = 0.3937.
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Figure 4.3. Soleus maximal rate of force decline. SED, sedentary; RT, resistance
training; K, Krebs-Henseleit buffer; Cr, Creatine; DOX, doxorubicin. No main effects or
interactions.

Figure 4.4. Extensor digitorum longus maximal twitch force. SED, sedentary; RT,
resistance training; K, Krebs-Henseleit buffer; Cr, Creatine; DOX, doxorubicin. No main
effects or interactions.
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The analysis of EDL maximal rate of force development revealed no significant
main effects from activity, F(1, 66) = 0.52, p = 0.4739; drug F(1, 66) = 0.01, p = 0.9355;
or nutrition, F(1, 66) = 0.69, p = 0.4091 (see Figure 4.5). Moreover, the interaction of
activity and drug was not significant, F(1, 66) = 0.92, p = 0.3415. In addition, activity
and nutrition did not result in a significant interaction, F(1, 66) = 0.17, p = 0.6858 nor
was the combination of drug and nutrition, F(1, 66) = 0.18, p = 0.6750. Also, no
significant three-way interaction among activity, drug, and nutrition was observed, F(1,
66) = 0.20, p = 0.6568.
As Figure 4.6 depicts, no main effect from activity, F(1, 65) = 0.91, p = 0.3524;
drug, F(1, 65) = 0.87, p = 0.3543; or nutrition, F(1, 65) = 0.45, p = 0.5040, was observed
for EDL maximal rate of force decline. Additionally, no significant interactions between
activity and drug, F(1, 65) = 1.27, p = 0.2637; activity and nutrition, F(1, 65) = 1.60, p =
0.2098; or drug and nutrition, F(1, 65) = 1.27, p = 0.2640, were noted. Similarly, the
three way interaction among activity, drug, or nutrition was not significant, F(1, 65) =
0.02, p = 0.8911.
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Figure 4.5. Extensor digitorum longus maximal rate of force development. SED,
sedentary; RT, resistance training; K, Krebs-Henseleit buffer; Cr, Creatine; DOX,
doxorubicin. No main effects or interactions.

Figure 4.6. Extensor digitorum longus maximal rate of force decline. SED, sedentary;
RT, resistance training; K, Krebs-Henseleit buffer; Cr, Creatine; DOX, doxorubicin. No
main effects or interactions.
.
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Fatigue
After determination of maximal twitch characteristics and the buffers refreshed
with K, the muscles were stimulated once per second for 100 seconds. Forces were then
recorded every 10 seconds. Significant reductions from baseline in the SOL were seen at
70, 50, and 50 seconds for SED-K-K, SED-Cr-DOX, and SED-K-DOX, respectively.
Conversely, SED-Cr-K did not have a significant drop from baseline during the observed
time period, which indicated that Cr did delay the onset of fatigue. The addition of RT to
the SOL produced a profoundly different response. A significant drop from baseline was
observed at 60 seconds for RT-K-K and 60 seconds for RT-K-DOX; however, the
addition of RT delayed the onset of fatigue until 100 seconds for RT-Cr-DOX. No
significant drop from baseline was found for RT-Cr-K group. Soleus fatigue data can be
seen in Figure 4.7.
Sedentary-K-K fatigue for the EDL was significantly different from baseline at 60
seconds. With the addition of Cr, however, a significant reduction from baseline was not
observed during the stimulation period. At the 50 second time point, SED-K-DOX was
significantly lower than baseline. Sedentary-Cr-DOX was significantly lower than
baseline at the 60 second time point. Significant reductions from baseline were found at
50 seconds for RT-K-DOX and 60 seconds for RT-K-K. The application of Cr delayed
the onset of fatigue to 70 seconds in RT-Cr-DOX. This highlighted RT’s unique
response on fatigue rates in the EDL. Without DOX, the combination of RT and Cr did
not result in a significant drop from baseline. Resistance training EDL fatigue data can
be seen in Figure 4.8.
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Figure 4.7. Soleus fatigue rates for a 100 second fatigue for the soleus of sedentary
animals (A) and for the soleus of resistance trained animals (B). SED, sedentary; RT,
resistance training; K, Krebs-Henseleit buffer; Cr, Creatine; DOX, doxorubicin. Symbols
indicate significant reductions from baseline. † K+K, significantly lower than baseline (p
< 0.05), ‡ K+DOX, significantly lower than baseline (p < 0.05), and # Cr+DOX,
significantly lower than baseline (p < 0.05).
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Figure 4.8. Fatigue rates for a 100 second fatigue for the extensor digitorum longus of
sedentary animals (A) and for the extensor digitorum longus of resistance trained animals
(B). SED, sedentary; RT, resistance training; K, Krebs-Henseleit buffer; Cr, Creatine;
DOX, doxorubicin. Symbols indicate significant reductions from baseline. † K+K,
significantly lower than baseline (p < 0.05), ‡ K+DOX, significantly lower than baseline
(p < 0.05), and # Cr+DOX, significantly lower than baseline (p < 0.05).
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Creatine Content
Tissue Cr concentration was analyzed using the left SOL and EDL from SED-KK, Sed-Cr-K, RT-K-K, and RT-Cr-K animals. To test the effect of activity (RT and
SED) and nutrition (Cr or K) on muscle Cr content, a two way ANOVA was performed.
In the SOL, The results showed no significant main effect of activity, F(1, 24) = 0.8469,
p = 0.3666, or nutrition, F(1, 24) = 0.7668, p = 0.3899; however, there was a significant
interaction between activity and nutrition on SOL Cr content, F(1, 24) = 4.760, p =
0.0392. As can be seen in Figure 4.9, in the RT condition, SOL muscles incubated with
Cr had higher Cr content than non-treated controls. To explore this effect further,
Tukey’s multiple comparison tests were performed and no significant differences in
intracellular Cr were observed (p > 0.05).
In the EDL, there was a significant main effect, F(1, 24) = 6.129, p = 0.0207, of
nutrition on total intracellular Cr concentration; however, no significant activity effect
was observed, F(1, 24) = 1.119, p = 0.3006, and there were no significant interactions,
F(1, 24) = 0.5208, p = 0.4775 (see Figure 13). Tukey’s post hoc testing did not show any
significant differences between the groups (p > 0.05; see Figure 4.10).
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Figure 4.9. Soleus creatine concentration. SED, sedentary; RT, resistance training; K,
Krebs-Henseleit buffer; Cr, Creatine. Significant interaction between activity (RT) and
nutrition (Cr), F(1, 24) = 4.760, p = 0.0392.

Figure 4.10. Extensor digitorum longus creatine concentration. SED, sedentary; RT,
resistance training; K, Krebs-Henseleit buffer; Cr, Creatine. Significant main effect
nutrition (Cr), F(1, 24) = 6.129, p = 0.0207.
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Conclusions
With regard to the hypotheses, the following statistical conclusions were
warranted.
1.

With regard to the capacity of RT to protect against DOX-induced
myotoxicity by preserving maximal twitch force, the statistical analysis
rejected H1; however, the analysis of fatigue showed that RT delayed
fatigue in the SOL but not in the EDL. Thus, statistically, H1 could not be
completely rejected.

2.

With respect to the ability of Cr to minimize DOX-induced myotoxicity by
preserving maximal twitch force, the statistical findings rejected H2.
Conversely, the statistical findings, with respect to capacity of Cr to
minimize fatigue, suggested Cr could delay the onset of fatigue in the EDL
but not in the SOL. Thus, H2 could not be completely rejected.

3.

With respect to the ability of RT and Cr to provide a greater level of
protection against DOX-induced myotoxicity than either treatment
administered separately, the statistical results failed to reject H3. The results
indicated the combination of RT and Cr could result in a substantial
protection against DOX-induced fatigue.

4.

In the determination of the ability of Cr to increase total Cr, the findings
indicated Cr treatment did not increase total Cr. Thus, H4 was rejected.

CHAPTER V

MANUSCRIPT

Introduction
Use of the anthracycline chemotherapeutic drug doxorubicin (DOX) is associated
with a number of debilitating side effects, such as its dose dependent cardiotoxicity and
more recently discovered myotoxicity. The cardiotoxicity is commonly manifested in the
form of dilated cardiomyopathy and congestive heart failure (Chatterjee et al., 2010).
The mechanisms behind these negative effects are partly the result of an increase in
oxidative stress (Gilliam & St Clair, 2011), an increase in intracellular iron (Ichikawa et
al., 2014), inhibition of NRG1/Erb signaling cascade (Vasti et al., 2012), and a reduction
in high-energy phosphates (Maslov et al., 2010). In addition, impairment of progenitor
cell renewal, cardiac repair, and decreased vasculogenesis are common with DOX
treatment (Menna et al., 2008; Y. Shi et al., 2011). To date, no pharmacological agent
can prevent these side effects; however, aerobic exercise has been used effectively as a
means for attenuating the decline in cardiac function (Chicco et al., 2005; Hydock et al.,
2008; Wonders et al., 2008).
There is growing evidence that DOX not only has cardiotoxic effects but can also
negatively affect skeletal muscle function (Ascensao et al., 2011; Hydock et al., 2011;
van Norren et al., 2009). Although there is broad consensus that DOX has a negative
impact on skeletal muscle function, the specific mechanisms behind this dysfunction
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remain elusive despite several proposed explanations. For example, Gilliam and St Clair
(2011) suggested the skeletal muscle dysfunction could be a result of the variation in
tumor necrosis factor receptor. Similarly, van Noreen et al. (2009) identified the
dysfunction as resulting from changes in calcium (Ca2+ ) handling, while Abramson et al.
(1988) attributed it to disruptions in the sarcoplasmic reticulum (SR). Another possibility
is that DOX interferes with key Ca2+ skeletal muscle handling proteins such as the
sarcoendoplasmic reticulum calcium ATPase (SERCA; Abramson et al., 1988). This
protein is instrumental in Ca2+ uptake during skeletal muscle relaxation (Periasamy &
Kalyanasundaram, 2007). These findings help explain DOX-induced dysfunction from a
functional standpoint, but the effects of DOX are not limited to interference with Ca2+
alone.
Part of the myotoxic effects of DOX can be attributed to its generation of reactive
oxygen species (ROS). It is plausible that the rise in ROS could be the culprit in the
observed DOX-induced muscle dysfunction. Furthermore, cardiac myocytes treated with
DOX display a decrease in their overall antioxidant capacity (Wallace, 2003).
Additionally, in diaphragm muscle treated with DOX, there is a similar reduction in
antioxidant capabilities (Gilliam et al., 2011). This antioxidant reduction is further
evidenced by the activation of caspase-3, a key regulatory component of apoptosis
triggered by high levels of oxidative stress (Smuder et al., 2011). This increase in free
radical production could lead to an altered functional capacity of the SR, possibly through
lipid peroxidation. Furthermore, altered Ca2+ handling via damaged SR could interfere
with normal cross bridge cycling, which could account for some of the increased
muscular fatigue commonly seen during DOX treatment.
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There is mounting evidence that exercise can minimize cancer related fatigue and
improve quality of life (Quist et al., 2006; Spence et al., 2010). Furthermore, evidence
suggests that exercise, in general, is safe and effective during the administration of
adjuvant cancer therapies (Cheema et al., 2008; Jones & Demark-Wahnefried, 2006;
McNeely et al., 2006). However, the appropriate modalities and dosages required to
produce these positive effects have yet to be fully elucidated. Even with the prevailing
focus upon the effectiveness of aerobic exercise, there is a growing body of evidence
supporting the benefits of other forms of exercise (Focht et al., 2013). For example, it is
well known that resistance training (RT) yields a number of favorable adaptations that
could be effective at reducing the physiological and quality of life outcomes in cancer
patients and survivors.
Resistance training produces a wide range of adaptations such as improved
muscular performance, hypertrophy, improved body composition, increased appetite, and
increased bone strength (Winett & Carpinelli, 2001) . Moreover, RT has been used as a
means of palliative care and has been shown to reduce cancer-related fatigue (Adamsen
et al., 2009; Meneses-Echavez et al., 2014), improve muscular strength in patients with
heart failure (Gielen et al., 2014), preserve muscle mass in patients with heart failure
(Gielen et al., 2014), promote increased blood cell counts in those undergoing
chemotherapy (Karvinen et al., 2014), and improve breast cancer outcomes during
chemotherapy (Courneya et al., 2014). The benefits from resistance training stand in
sharp contrast to myotoxicity seen with DOX. Thus, one purpose of this study was to
examine the effects of RT on DOX-induced muscle dysfunction.
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Creatine monohydrate (Cr) is a popular ergogenic aid and its benefits on the
phosphagen system have been well studied (Clark, 1997; Kraemer & Volek, 1999; Persky
& Brazeau, 2001). Previous research has demonstrated that when skeletal muscle is
incubated in an ex vivo tissue bath with Cr, there is an increase in force production and
improved rates of time to fatigue (Head et al., 2011). In addition, Eisner et al. (2014)
demonstrated that supplemental Cr improves the rates of muscle fatigue in mice with
mitochondrial dysfunction. Drawing on the model of DOX-induced muscle dysfunction,
deficits in energy metabolism are believed to be one of the mechanisms that lead to
DOX-induced muscle dysfunction. Doxorubicin has been shown to decrease high-energy
phosphates and alter the ratio of phosphocreatine (PCr) to adenosine triphosphate (ATP;
Darrabie et al., 2012; Maslov et al., 2010; Ohhara et al., 1981; Seraydarian et al., 1977).
Furthermore, it has also been noted that DOX can lower levels of Cr and creatine kinase
(CK) in cardiac myocytes (Tokarska-Schlattner et al., 2006). The possibility of a
reduction of ATP and a reduced PCr and ATP ratio could help explain DOX-induced
muscle dysfunction from an energy standpoint.
A major purpose of this study involved the examination of the effects of
incubating muscles ex vivo with Cr prior to treatment with DOX in order to minimize
muscle dysfunction. In addition, another purpose of this study was to examine the effects
of a combined treatment of RT and Cr to minimize DOX-induced muscle dysfunction.
Furthermore, this study hypothesized that Cr in combination with RT had the possibility
of greatly attenuating DOX-induced myotoxicity. To date, there is a gap in the literature
as to the effects RT has on DOX treated skeletal muscle with and without Cr
supplementation. It is important to develop a better explanation of these factors because

63
they might be an effective treatment strategy in the palliative care of those undergoing
chemotherapy with DOX.
Methods
All procedures were approved by the University of Northern Colorado’s
Institutional Animal Care and Use Committee (IACUC). Ten week-old male SpragueDawley rats (N=64) weighing approximately 300 grams were used in this study.
Animals were housed two per cage in standard 20.32 cm high and 26.67 cm wide by
48.26 cm deep plastic rat cages and maintained on a 12hr/12hr light/dark cycle in a
temperature and humidity controlled environment. Animals had access to standard chow
and distilled water ad libitum for the duration of the study.
Training Protocol
Animals were randomly assigned to either an RT group (n = 32) or a sedentary
(SED) group (n = 32) for six weeks. A six week RT training protocol was used because
it has been reported to be the minimal amount of time necessary to reduce fatigue,
improve muscular strength, and increase physical and functional activity in cancer
patients undergoing chemotherapy (Adamsen et al., 2009). Resistance training was
simulated by placing rats in cages where the food and water was progressively elevated
over the course of two weeks until reaching a final height of 0.2 meters above normal.
Animals remained in the elevated food and water cages for an additional four weeks (six
weeks total). This elevated height caused the rats to rise to a bipedal stance or jump to
reach their food and water, thus providing a representative model for chronic hind-limb
loading and RT. This model has been shown to increase hypertrophy of the hind-limb
muscles and increase hind-limb bone density while minimizing animal distress (Yao et
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al., 2001). Animals assigned to the SED group were kept in standard cages for an
equivalent amount of time. At the end of the training period, animals were further
divided into four groups (n = 16) based on the first treatment buffer (Cr or K). Next,
animals were further divided into eight groups based on the second treatment buffer
(DOX or K). An illustration of the experimental design can be seen in Figure 5.1.

Figure 5.1. Illustration of experimental design. Abbreviations: RT- Resistance Training;
SED- Sedentary; Cr- Creatine Monohydrate; Krebs- Krebs-Henseleit Buffer.

Muscle Function, Creatine, and Doxorubicin
After six weeks of RT or SED, each animal was anesthetized with an
intraperitoneal injection of heparinized sodium pentobarbital (50 mg/kg). When the
animal was anesthetized, and a tail pinch reflex was absent, the right and left soleus
(SOL) and extensor digitorum longus (EDL) were excised and placed in oxygenated
(95% O2 and 5%CO2) Krebs-Henseleit buffer (K) (120 mM NaCl, 5.9 mM KCl, 2.5 mM
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CaCl2, 1.2 mM MgCl, 25 mM NaHCO3, 17 mM glucose, pH 7.4) heated to 37°C.
Excised tissues were given two minutes to recover from surgery, and then the muscle was
mounted in an ex vivo muscle function apparatus. The proximal end of the muscle was
then attached to a spring clip connected to a force transducer. The distal end was
attached to a stationary glass hook. Muscle characteristics (maximal twitch force,
maximal rate of force development, and maximal rate of force decline) were recorded
through ADInstruments Lab Chart software (Colorado Springs, CO). Functional data
were only collected from the SOL and EDL from the right hind limb. The muscles from
left hind limb of non-DOX treated animals underwent the same treatment process as the
right sided muscle but without any functional testing.
Following the recovery period and prior to the first incubation, optimal maximal
twitch characteristics were determined and recorded for the muscles of the right hind
limb as described previously (Hydock et al., 2011). Following maximal twitch
determination, the muscle was exposed to the first treatment buffer consisting of a K
buffer or K buffer containing Cr (25 mM) for 30 minutes. During the incubation period,
the muscle was stimulated at 100 Hz for 200 msec every five minutes using the
established twitch settings. This stimulation protocol has been previously shown to
facilitate movement and activation of the Cr transporter (CreaT; Head et al., 2011).
Following the 30 minute incubation period, the buffer was changed to the second
treatment buffer (K or K buffer with DOX [24 µM]), and both sets of muscles were
allowed to incubate for another 30 minutes. A DOX concentration of 24 µM was used
since it represented the upper limits for serum concentrations immediately following
infusion with DOX (Baurain et al., 1982). The muscles were stimulated again for 200

66
msec at 100 Hz once every five minutes for the duration of second incubation using the
same voltage as before. At the end of the last incubation period, the left hind limb
muscles from all non-DOX treated animals were removed from the tissue bath, weighed,
flash frozen in liquid nitrogen, and stored in a -80°C freezer for later biochemical
analysis.
The buffers were replaced again with fresh K buffer, and muscle characteristics
were reassessed using the initial maximal twitch settings. Following reassessment of
maximal twitch, the tissues were supplied with fresh K and analyzed for fatigue. Fatigue
rate was determined using the same voltage settings from maximal twitch determination
with a frequency of 83 Hz and pulse duration of 500 ms (square wave pulses). Muscles
were stimulated to contract every second for 100 seconds, and twitch forces through the
course of the protocol were recorded.
Creatine Content
A portion of the left SOL or EDL was added to an Eppendorf tube along with a
1:4 weight/volume ratio of Creatine assay buffer (Sigma Aldrich, St. Louis, MO) and
homogenized (ScilogexD160 homogenizer; Rocky hill, CT). After five minutes of
homogenization, the homogenates were centrifuged through a 17 KDa micro spin filter at
10,000 g for 10 minutes at 4℃. After centrifugation, the supernatant was collected, and
its total protein concentration was determined using the Bradford protein assay method
(Bradford, 1976). Finally, 30µl of each sample was loaded on to a 96 well plate.
Analysis of creatine content was done using the Sigma Aldrich creatine assay kit
(MAK079, Sigma Aldrich, St. Louis, MO). Samples and standards (0, 2, 4, 6, 8, and 10
nmole/well) were prepared and treated according to the manufacturers specifications.
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Samples were analyzed at 570 nm using a 96 well plate reader (BioTek elx800,
Winooski, VT) to determine total Cr content.
Statistical Analysis
All data were presented as mean ± standard deviation (mean ± SD). A threefactor analysis of variance (ANOVA) was used to determine main effects and interactions
for the three treatments--RT, Cr, and DOX. Tukey’s post-hoc analysis was used to
determine significance between treatment combinations on maximal twitch
characteristics and Cr content. The dependent variables for maximal twitch
characteristics were maximal twitch force, maximal rate of force development, and
maximal rate of force decline. A two-way ANOVA was used to determine the effects of
RT and Cr on muscle Cr content. Tukey’s post-hoc analysis was used to determine
significance between the groups. The dependent variable for Cr content was the
measured Cr concentration. Fatigue was analyzed over time using repeated measures
ANOVA with a Dunnett’s post-hoc analysis. A significance level of α = 0.05 was used
for all statistical analyses. Graph Pad Prism (San Diego, CA) was used for statistical
analysis.
Results
Doxorubicin is a powerful chemotherapy agent with potent anticancer properties,
but it can cause severe disruptions in normal skeletal muscle function. The specific
mechanisms behind this dysfunction have yet to be fully explained; however, they are
likely the result of a combination of excess levels of ROS and interference in ATP
availability. Thus, it might be possible to minimize the DOX-induced muscle
dysfunction with either Cr or RT. Individually, each of these could offer a reprieve from
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the harmful effects of DOX. In combination, they have the possibility of providing
substantial protection against DOX-induced muscle dysfunction.
General Observations
Prior to incubation, each animal was weighed and body mass recorded. An
unpaired t-test was performed to determine if the body masses were significantly
different. Resistance training animals had a significantly higher body mass of 393 ± 31
grams when compared to the body mass of 350 ± 29 grams in the SED, p <0.0001.
Furthermore, RT resulted in a significantly higher SOL mass than those in the SED
group, p <0.0001. No significant differences were found EDL mass. Muscle weights can
be seen in Table 1.

Table 5.1
Muscle Masses
Group

L-SOL (g)

L-EDL (g)

Sedentary

0.2109±0.01

0.1975±0.03

Resistance Training

0.2496±0.07

0.2227±0.04

Maximal Twitch Characteristics
Following the incubation periods, maximal twitch characteristics (maximal twitch
force, maximal rate of force development, and maximal rate of force decline) were
assessed and recorded. The selected maximal twitch variables can be seen in Figures 5.25.7. A three-way ANOVA was performed to assess the main effects and interactions of
activity (RT or SED), drug (DOX or K), and nutrition (Cr or K) on each maximal twitch
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characteristics in the SOL and EDL. As Figure 5.2 shows, no significant drug effect
existed for SOL maximal twitch force, F(1, 70) = 0.08, p = 0.7744. Likewise, nutrition
had no significant effect on SOL maximal twitch, F(1, 70) = 0.37, p = 0.5437; however,
there was a significant activity effect, F(1, 70) = 5.83, p = 0.0184. In general, SED
animals had a higher SOL max twitch than RT animals. Furthermore, a trend toward an
interaction of drug and activity was found on SOL maximal twitch force, F(1, 70) = 3.47,
p = 0.0667. No significant interactions existed between activity and nutrition, F(1, 70) =
0.10, p = 0.7524, or nutrition and drug, F(1, 70) = 0.53, p = 0.698. There was also no
statistically significant three-way interaction among activity, drug, and nutrition, F(1, 70)
= 0.37, p = 0.05430. To examine the significant effects further, Tukey’s multiple
comparison tests were performed, and no significant differences between the groups were
observed (see Figure 5.2, p > 0.05).
When examining SOL maximal rate force development, no significant main
effects from activity, F(1, 69) = 0.10, p = 0.7482; drug, F(1, 69) = 0.15, p = 0.6966; or
nutrition, F(1, 69) = 0.05, p =0.8265, were found (see Figure 5.3). In addition, no
significant interactions were observed aiming activity and drug, F(1, 69) = 0.03, p =
0.8536; activity and nutrition, F(1, 69) = 0.00, p = 0.9713; or nutrition and drug, F(1, 69)
= 2.31, p = 0.1329. Furthermore, no significant three-way interaction existed among
activity, drug, and nutrition, F(1, 69) = 0.67, p = 0.4163.
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Figure 5.2. Soleus maximal twitch force. SED, sedentary; RT, resistance training; K,
Krebs-Henseleit buffer; Cr, Creatine; DOX, doxorubicin. Significant activity effect, F(1,
70) = 5.83, p =0.0184.

Figure 5.3. Soleus maximal rate of force development. SED, sedentary; RT, resistance
training; K, Krebs-Henseleit buffer; Cr, Creatine; DOX, doxorubicin. No main effects or
interactions.
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Similarly, as illustrated in Figure 5.4, no significant main effects for activity, F(1,
69) = 0.08, p = 0.7846; drug, F(1, 69) = 0.06, p = 0.7689; or nutrition, F(1, 69) = 0.00, p
= 0.9559, were observed for SOL maximal rate of force decline. Likewise, no significant
interactions from either activity and drug, F(1, 69) = 0.00, p = 0.9510; activity and
nutrition, F(1, 69) = 0.03, p = 0.8542; or nutrition and drug, F(1, 69) = 1.54, p = 0.2182,
were observed on SOL maximal rate of force decline. Finally, no significant three-way
interaction was observed among activity, drug, and nutrition, F(1, 69) = 0.42, p = 0.5178,
on SOL maximal rate of force decline.
In the EDL, no significant main effects from the drug existed on EDL maximal
twitch force, F(1, 68) = 0.02, p = 0.8865. Similarly, no significant main effects were
detected with either the activity, F(1, 68) = 0.0, p = 0.9609; or drug, F(1, 68) = 0.02, p =
0.8865 on EDL maximal twitch force (see Figure 5.5). In addition, no interactions were
observed between activity and drug, F(1, 68) = 1.17, p = 0.2839; activity and nutrition,
F(1, 68) = 0.28, p = 0.5999, or drug and nutrition F(1, 68) = 0.30, p = 0.5837 on EDL
maximal twitch force. No significant three way interaction among activity, drug, or
nutrition was detected, F(1, 68) = 0.74, p = 0.3937.

72

Figure 5.4. Soleus maximal rate of force decline. SED, sedentary; RT, resistance
training; K, Krebs-Henseleit buffer; Cr, Creatine; DOX, doxorubicin. No main effects or
interactions.

Figure 5.5. Extensor digitorum longus maximal twitch force. SED, sedentary; RT,
resistance training; K, Krebs-Henseleit buffer; Cr, Creatine; DOX, doxorubicin. No main
effects or interactions.
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The analysis of EDL maximal rate of force development revealed no significant
main effects from activity, F(1, 66) = 0.52, p = 0.4739; drug F(1, 66) = 0.01, p = 0.9355;
or nutrition, F(1, 66) = 0.69, p = 0.4091 (see Figure 5.6). Moreover, the interaction of
activity and drug was not significant, F(1, 66) = 0.92, p = 0.3415. In addition, activity
and nutrition did not result in a significant interaction, F(1, 66) = 0.17, p = 0.6858 nor
was the combination of drug and nutrition, F(1, 66) = 0.18, p = 0.6750. Also, no
significant three-way interaction among activity, drug, and nutrition was observed, F(1,
66) = 0.20, p = 0.6568.
As Figure 5.7 depicts, no main effect from activity, F(1, 65) = 0.91, p = 0.3524;
drug, F(1, 65) = 0.87, p = 0.3543; or nutrition, F(1, 65) = 0.45, p = 0.5040, was observed
for EDL maximal rate of force decline. Additionally, no significant interactions between
activity and drug, F(1, 65) = 1.27, p = 0.2637; activity and nutrition, F(1, 65) = 1.60, p =
0.2098; or drug and nutrition, F(1, 65) = 1.27, p = 0.2640, were noted. Similarly, the
three way interaction among activity, drug, or nutrition was not significant, F(1, 65) =
0.02, p = 0.8911.
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Figure 5.6. Extensor digitorum longus maximal rate of force development. SED,
sedentary; RT, resistance training; K, Krebs-Henseleit buffer; Cr, Creatine; DOX,
doxorubicin. No main effects or interactions.

Figure 5.7. Extensor digitorum longus maximal rate of force decline. SED, sedentary;
RT, resistance training; K, Krebs-Henseleit buffer; Cr, Creatine; DOX, doxorubicin. No
main effects or interactions.
.
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Fatigue
After determination of maximal twitch characteristics, and the buffers refreshed
with K, the muscles were stimulated once per second for 100 seconds. Forces were then
recorded every 10 seconds. Significant reductions from baseline in the SOL were seen at
70, 50, and 50 seconds for SED-K-K, SED-Cr-DOX, and SED-K-DOX, respectively.
Conversely, SED-Cr-K did not have a significant drop from baseline during the observed
time period, which indicated that Cr did delay the onset of fatigue. The addition of RT to
the SOL produced a profoundly different response. A significant drop from baseline was
observed at 60 seconds for RT-K-K, and 60 seconds for RT-K-DOX; however, the
addition of RT delayed the onset of fatigue till 100 seconds for RT-Cr-DOX. No
significant drop from baseline was found for RT-Cr-K group. Soleus fatigue data can be
seen in Figure 5.8.
Sedentary-K-K fatigue for the EDL was significantly different from baseline at 60
seconds. With the addition of Cr, however, a significant reduction from baseline was not
observed during the stimulation period. At the 50 second time point, SED-K-DOX was
significantly lower than baseline. Sedentary-Cr-DOX was significantly lower than
baseline at the 60 second time point. Significant reductions from baseline were found at
50 seconds for RT-K-DOX and 60 seconds for RT-K-K. The application of Cr delayed
the onset of fatigue to 70 seconds in RT-Cr-DOX. This highlighted RT’s unique
response on fatigue rates in the EDL. Without DOX, the combination of RT and Cr did
not result in significant drop from baseline. Resistance training EDL fatigue data can be
seen in Figure 5.9.
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Figure 5.8. Soleus fatigue rates for a 100 second fatigue for the soleus of sedentary
animals (A) and for the soleus of resistance trained animals (B). SED, sedentary; RT,
resistance training; K, Krebs-Henseleit buffer; Cr, Creatine; DOX, doxorubicin. Symbols
indicate significant reductions from baseline. † K+K, significantly lower than baseline (p
< 0.05), ‡ K+DOX, significantly lower than baseline (p < 0.05), and # Cr+DOX,
significantly lower than baseline (p < 0.05).
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Figure 5.9. Extensor digitorum longus fatigue rates. Fatigue rates for a 100 second
fatigue for the extensor digitorum longus of sedentary animals (A) and for the extensor
digitorum longus of resistance trained animals (B). SED, sedentary; RT, resistance
training; K, Krebs-Henseleit buffer; Cr, Creatine; DOX, doxorubicin. Symbols indicate
significant reductions from baseline. † K+K, significantly lower than baseline (p < 0.05),
‡ K+DOX, significantly lower than baseline (p < 0.05), and # Cr+DOX, significantly
lower than baseline (p < 0.05).

78
Creatine Content
Total Cr concentration was analyzed using the left SOL and EDL from SED-K-K,
Sed-Cr-K, RT-K-K, and RT-Cr-K animals. To test the effect of activity (RT and SED)
and nutrition (Cr or K) on muscle Cr content, a two way ANOVA was performed. In the
SOL, results showed no significant main effect of activity, F(1, 24) = 0.8469, p = 0.3666,
or nutrition, F(1, 24) = 0.7668, p = 0.3899; however, there was a significant interaction
between activity and nutrition on SOL Cr content, F(1, 24) = 4.760, p = 0.0392. As can
be seen in Figure 5.10, in the RT condition, SOL tissue incubated with Cr had higher Cr
content than non-treated controls. To explore this effect further, Tukey’s multiple
comparison tests were performed and no significant differences in intracellular Cr were
observed (p > 0.05).
In the EDL, there was a significant main effect, F(1, 24) = 6.129, p = 0.0207, of
nutrition on total intracellular Cr concentration; however, no significant activity effect
was observed, F(1, 24) = 1.119, p = 0.3006, and there was no significant interactions,
F(1, 24) = 0.5208, p = 0.4775 (see Figure 5.10). Tukey’s post hoc testing did not show
any significant differences between the groups (p > 0.05; see Figure 5.11).
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Figure 5.10. Soleus creatine concentration. SED, sedentary; RT, resistance training; K,
Krebs-Henseleit buffer; Cr, Creatine. Significant interaction between activity (RT) and
nutrition (Cr), F(1, 24) = 4.760, p = 0.0392.

Figure 5.11. Extensor digitorum longus creatine concentration. SED, sedentary; RT,
resistance training; K, Krebs-Henseleit buffer; Cr, Creatine. Significant main effect
nutrition (Cr), F(1, 24) = 6.129, p = 0.0207.
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Discussion
Resistance training (RT) represents a therapeutic intervention that could be
utilized to improve the lives of cancer patients. In fact, RT has been used as a means of
palliative care and has been shown to reduce cancer-related fatigue (Adamsen et al.,
2009; Meneses-Echavez, Gonzalez-Jimenez, & Ramirez-Velez, 2014), improve muscular
strength in patients with heart failure (Gielen, Laughlin, O'Conner, & Duncker, 2014),
preserve muscle mass in patients with heart failure (Gielen et al., 2014), promote
increased blood cell counts in those going through chemotherapy (Karvinen, Esposito,
Raedeke, Vick, & Walker, 2014), and improve breast cancer outcomes during
chemotherapy (Courneya et al., 2014). More importantly, RT has been shown to be
beneficial for minimizing fatigue and improving quality of life in cancer patients
(Courneya & Friedenreich, 1999). These benefits demonstrate the powerful benefits that
can occur with RT. Thus, it can be concluded that RT can be used to minimize DOXinduced muscle dysfunction. However, there is substantially less information about the
appropriate dosages for the application of RT. It is important that further studies be done
to identify the appropriate application of RT and in a manner that is clinical relevant to
cancer patients.
Current evidence suggests a RT period from six weeks to six months is required
to minimize the side effects of the cancer treatment process. Given the meaningful
improvements in a wide variety of physiological and quality of life outcomes during the
cancer treatment process, it can be concluded that RT could and should be incorporated
into the treatment plans of cancer patients. However, there is a great deal of variability in
the improvements seen with RT (Focht et al., 2013). In general, evidence does suggest
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that RT will produce a statistically significant increase in muscular strength, muscular
endurance, improvements in physical function, and some improvements in quality of life
(Howlader et al., 2013; Speck et al., 2010). Due to different cancer types, the kinds of
treatment, and treatment stage at which the RT was implicated, it can be difficult to
extrapolate these findings to general recommendations for cancer rehabilitation
professionals. Animal-based studies, on the other hand, can provide an alternative to the
compounding variables commonly seen with clinical type studies. With these types of
studies, scientists can develop treatment recommendations based on the treatment type
and level; it also allows the researcher a tremendous amount of control over the exercise
intervention.
Aerobic exercise has been used to minimize DOX-induced cardiac dysfunction
(Wonders et al., 2008; Chico et al., 2006), improve the antioxidants status (Ascensao et
al., 2011), and improve vascular function (Gibson et al., 2013). However, to our
knowledge, no study has been conducted on the ability of exercise to minimize DOXinduced muscle dysfunction. The usefulness of aerobic training to minimize DOXinduced muscle dysfunction still remains to be determined, but given the functional
capacity of cancer patients, RT is perhaps the best choice for an exercise intervention to
minimize DOX-induced muscle dysfunction. Resistance training by its nature can
improve strength and muscular endurance, which could enhance the ability of cancer
patients to perform ADL and minimize treatment-related fatigue.
The current study demonstrated the effects of DOX, Cr, and RT individually and
in combination on DOX-induced muscle dysfunction. Given that DOX treatments
commonly result in skeletal muscle dysfunction via changes in enzymatic (Smuder et al.,
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2011), morphological (Stathopoulos et al., 1996), contractile (van Norren et al., 2009),
and calcium handling (De Beer et al., 1992), cancer patients might require treatments that
could augment multiple facets of skeletal muscle function. Despite the complex nature of
these mechanisms, this study was able to show that resistance training in combination
with Cr could mitigate DOX-induced muscular fatigue.
The skeletal muscle dysfunction seen with DOX treatment was unique in that it
might stem from the cardiac dysfunction caused by DOX (Chicco et al., 2006; Hydock et
al., 2008), and it has long been known that heart failure can lead to skeletal muscle
wasting and changes in the contractile properties of skeletal muscle (Gosker, Wouters,
van der Vusse, & Schols, 2000). However, identifying the exact cause of DOX-induced
muscle dysfunction is complex because those who are undergoing DOX treatment are
likely to have a number of secondary disease processes such as inadequate energy
consumption, skeletal muscle disuse and atrophy, cachexia, or other syndromes that make
it difficult to identify the true mechanism behind DOX-induced muscle dysfunction.
These secondary disease processes might enhance the effects of heart failure (Liu et al.,
2006), further contributing to the development of skeletal muscle dysfunction.
Although some mechanisms of DOX-induced muscle dysfunction have been
identified, much of its effects on skeletal muscle are still unknown. In addition to
secondary disease processes commonly accompanying the cancer treatments, we also
know that DOX has direct effects on skeletal muscle function (van Norren et al., 2009).
However, we show that Cr and RT could diminish DOX-induced muscle fatigue.
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Muscle Dysfunction
To our knowledge, this is the first study to examine the effects of RT and Cr on
DOX-induced muscle dysfunction. We show that incubation with DOX does not result in
the skeletal muscle dysfunction commonly seen with in vivo treatments. Previous studies
have shown that with lower frequency stimulation (40 Hz), there is an increase in
maximal force following incubation with DOX (van Norren et al., 2009). Van Noreen et
al. (2009) attributed the increase in maximal twitch force during low frequency
stimulation to an increase in free intra-cellular Ca2+. Work by Hydock et al. (2011)
demonstrated a significant reduction in muscle force with DOX treatment; however, the
dysfunction was more pronounced in the SOL than in the EDL. This is an important
finding that highlights the effects of DOX on oxidative muscle like the SOL.
Furthermore, evidence shows that treatment with DOX results in a significant decline in
EDL function (Ertunc et al., 2009; Hydock et al., 2011; van Norren et al., 2009). In the
current study, we were unable to find any significant reductions in maximal twitch
characteristics with DOX treatment in either the SOL or EDL, but there was a significant
main effect of RT on SOL maximal twitch. This finding suggested that, generally, RT
produced a lower maximal twitch force in the SOL; however, post hoc testing revealed
no significant differences between the groups. Contradictory results between this study
and previous in vivo studies were likely due to differences in methodology in DOX
administration. For example, work by van Noreen et al. (2009) showed that incubating
mouse EDL in 100 or 175 µM DOX for one hour or more resulted in a time- and
concentration-dependent decrease in maximal forces. In comparison, our investigation
used 30 minute incubation and a DOX concentration of 24 µM, which might not have
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been sufficient enough for DOX to exert its full myotoxic effects. A DOX concentration
of 24 µM was used because it represented the upper limits for serum concentrations
following infusion with DOX (Baurain et al., 1982). Thus, future investigations should
utilize multiple incubation periods to gain a better understanding of the effects of DOX
on skeletal muscle.
Fatigue
Doxorubicin use is associated with excessive patient fatigue and skeletal muscle
dysfunction (Fairclough, Fetting, Cella, Wonson, & Moinpour, 1999; Liu et al., 2006),
which can lead to significant reductions in the quality of life for cancer patients. Thus, it
is imperative to develop approaches that can help minimize these negative effects.
Fatigue represents a significant obstacle for cancer patients, and it can be reason to slow
or stop treatment altogether. Although fatigue is relatively common in cancer patients
going through the cancer treatment process, the exact mechanisms behind the observed
chemotherapy-induced fatigue remains elusive. Even in the in the healthy individual, it
can be extremely difficult to identify the exact cause of fatigue. Despite the complex
nature of fatigue, there is a wealth of literature documenting DOX’s effects on a variety
of tissues. To that end, DOX has been shown to interfere with normal mitochondrial
function, result in the excessive generation of ROS, and increase rates of atrophy (Giliam
et al., 2011). The impaired mitochondrial function could alter the amount ATP available
for normal cellular activities like cross bridge cycling and ion pumping. The increased
rates of ROS generation can quickly overwhelm endogenous antioxidants and lead to an
increase in protein and lipid oxidation, which can cause disruptions in normal organelle
and protein function. Furthermore, DOX has been shown to lead to increased rates of
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atrophy (Bonifati et al., 2000). This decrease in muscle mass as well as the compromised
cellular function provides a multicomponent explanation to observed DOX-induced
myotoxicity.
Although this study did not show significant reductions in maximal twitch
characteristics, it did show that DOX treated tissue had a faster time to fatigue than
untreated tissue. These results were in agreement with previous studies (Hydock et al.,
2011; van Norren et al., 2009). For instance, ex vivo work by Hydock et al. (2011)
demonstrated that DOX-induced fatigue in the SOL occurred at 20-30 seconds and at 70
seconds in untreated controls. Similarly, we showed that DOX treatment resulted in a
faster time to fatigue than untreated controls. In addition, evidence from this study
showed that RT prior to DOX treatment delayed the onset of fatigue by 10 seconds in the
SOL when compared to SED-K-DOX. Moreover, the combination of RT and Cr prior to
DOX was able to delay fatigue to the 100-second time point. This was an important
finding that highlighted the unique nature of RT and Cr in minimizing DOX-induced
SOL dysfunction and warrants further investigation.
This study demonstrated that treatment with DOX resulted in an earlier time to
fatigue by 10 seconds when compared to SED-K-K. Unlike in the SOL, prior RT did not
delay the onset of fatigue in the DOX-treated EDL. Conversely, Cr prior to DOX
treatment delayed the onset of fatigue, while including a combination of RT and Cr
before DOX helped delay the onset of fatigue by 20 seconds when compared to SEDDOX . Given that RT and Cr were able to delay the onset of fatigue beyond the effects of
RT or Cr alone suggested the combined effects of these treatments could be used to offset
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the myotoxic effects of DOX in cancer patients. Being able to mitigate the DOX-induced
fatigue could do much to improve their lives.
These findings provided the first evidence that the combination of Cr and RT
could be used to offset DOX-induced fatigue. Separately, Cr has been shown to improve
intracellular Cr stores (Persky & Brazeau, 2001), increase PCr resynthesis (Volek et al.,
2004), and act as antioxidant (Lawler et al., 2002). The ability to improve short-term
energy supply and minimize oxidative damage could explain some aspects of the reduced
fatigue rate. In addition, the ability to minimize DOX’s capacity for ROS generation
could help preserve mitochondrial integrity, which could help to preserve ATP
production and help maintain normal muscle function. Yet, as the results showed, it was
only in combination with RT when the DOX-induced fatigue was the least apparent.
Thus, in combination with Cr, there was an increase in short term energy supply and a
larger overall contractile apparatus capable utilizing the increase in ATP. In view of the
current findings, the combination of Cr and RT could do much to help minimize DOXinduced fatigue and improve the lives of those going through the cancer treatment
process.
Creatine Concentration
Creatine’s effectiveness as an ergogenic aid has been well documented in healthy,
trained, and diseased populations (Kreider, 2003). In the current investigation, a primary
objective was to determine if incubating muscle tissue in Cr would result in an increase in
total Cr levels. We also examined whether prior RT could have an effect on Cr content.
Results from this investigation indicated a significant interaction between the
combinations of RT and Cr toward a higher total Cr content; however, post hoc testing
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did not reveal any significant differences across groups. In the EDL, there was a
significant main effect from Cr on total Cr content. Although a significant main effect
was found, no significance between group differences was observed with post hoc
testing.
It should be noted that the Cr analysis used could not differentiate between Cr and
phosphocreatine (PCr). Although these results were encouraging and provided evidence
to warrant additional investigation, future studies should focus on the ratio of Cr to PCr.
This is an important consideration given the significance of the PCr-shuttle and its role in
maintaining ATP supply. Thus, it might be possible that the ratio of Cr to PCr could be
altered by Cr or RT. Furthermore, evidence also suggested that mitochondrial PCr stores
could change up to 100-fold when growth factors were removed (Vander Heiden et al.,
2000). Thus, it is plausible that Cr might preserve mitochondrial function in the DOX
treated cell by maintaining mitochondrial PCr stores. In addition to Cr effects on cellular
energy, Cr also exerts an antioxidant effect (Lawler et al., 2002). Lawler et al. (2002)
demonstrated that Cr acted as a direct antioxidant against radical ROS. Moreover, there
is evidence that Cr can prevent oxidative damage to mitochondrial DNA (mtDNA; Guidi
et al., 2008). Mitochondrial DNA is important because it can have profound effects on
the energy state of the cell and has recently been implicated in a variety of oxidative
stress disorders (Copeland, 2010). Taken together, these findings suggested that Cr could
be effective at minimizing oxidative damage caused by DOX, maintaining energy supply,
and preserving PCr stores.
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Summary
The present study examined the effects of RT and Cr on DOX-induced muscle
dysfunction within the SOL and EDL. Although this study did not show DOX-induced
alterations in maximal twitch characteristics commonly seen with in vivo studies, it did
show an earlier time to fatigue with DOX treatment in the SOL and EDL. Additionally,
this investigation demonstrated that RT and Cr in combination could attenuate fatigue in
the DOX-treated muscle. This finding provided the first evidence for the incorporation of
RT and Cr into the treatment plan to help minimize DOX-induced muscle dysfunction.
Adding RT and Cr to the treatment plan could provide cancer patients with an improved
quality of life and increased capacity to perform ADL. Although more research should
be done, these findings provided insight into the potential application of combined
treatment with RT and Cr to preserve function and offset the myotoxic effects of DOX.
Such evidence provided more support for the effectiveness and capacity of exercise and
nutritional interventions to improve functional capacity for cancer patients during their
treatment process.
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APPENDIX A
PILOT STUDY
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A pilot study using 10-week-old male Sprague-Dawley rats was conducted to
examine if Cr can mitigate the myotoxic effects of DOX. Animals were randomly
assigned to one of four experimental groups: K +K (n =7), K+DOX (n=7), Cr+ K (n = 8),
or Cr+DOX (n = 8). Three different buffers were made: K, Cr, and DOX. Each buffer
started with a basic K buffer (in mM, 120 NaCl, 5.9 KCl, 2.5 CaCl2, 1.2 MgCl2, 25
NaHCO3, 17 glucose, and 0.5 EDTA, pH 7.4). The Cr buffer used a K buffer with 25
mM of Cr. For the DOX buffer, a K buffer was affixed with 24 μM of DOX. The SOL
and EDL muscles from the right and left hind limb were excised and allowed to stabilize
for 5 min in aerated (95 % O2/5 % CO2) K buffer. Following stabilization, sutures with
micro-spring clips were attached to the distal and proximal tendons of each muscle, and
muscles were submerged in an organ chamber filled with K buffer. Muscle function was
analyzed using an ex vivo muscle function apparatus (Radnoti LLC, Monrovia, CA). The
proximal end of the muscle was affixed to an isometric force transducer; the distal end
was affixed to a stationary glass hook. Muscle function data were recorded via Lab Chart
software (ADInstruments, Colorado Springs, Colorado) following the attachment of the
muscles to the force transducer, maximal force determinations were made by adjusting
tension by 0.2 grams from a baseline of 0.5 grams until an increase in force is no longer
evident. Next, voltage was increased by 10 volts until maximal twitch force was
achieved.
Next, the buffers were changed to the corresponding treatment buffer (K or Cr).
During the incubation period, muscles were stimulated using platinum field stimulating
electrodes for 200 msec at 100 Hz once every five minutes for 30 minutes at the same
voltage achieved during the maximal force determinations. This stimulation helped
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facilitate Cr uptake into the cell. Then, the second treatment buffer was added (K or
DOX) and the muscles were again stimulated for 200 msec at 100 Hz once every five
minutes for 30 minutes using the same voltage as before. Following the second buffer
treatment, fresh K buffer was added and the muscles were again analyzed for maximal
twitch force. The fresh K buffer was again added, and the muscles were subjected to a
100 second fatigue protocol, during which muscle force was recorded every 10 seconds
for 100 seconds using the same voltage as before.
Examination of maximal twitch force (see Figures 1 and 2) showed an increase in
maximal twitch force with Cr administration in both the SOL and EDL when compared
to non-treated groups with the most pronounced differences occurring in the EDL.
Furthermore, pretreatment with Cr did not protect against DOX-induced muscle fatigue
in the SOL (see Figure 3). However, in the EDL, data did show some degree of Crinduced protection for attenuating fatigue (see Figure 4). Furthermore, Cr might have
had a more pronounced effect in type II (fast) muscle due to the higher levels of
phosphocreatine (PCr) and a greater reliance on the PCr system when compared to more
type I (slow) muscle. This suggested that Cr exerted a protective effect in skeletal
muscle.
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Figure 1. Maximal twitch force in the EDL. * vs. K+DOX & Cr+DOX(P < 0.05).

*

Figure 2. Maximal twitch force in the SOL. * vs. K+DOX (P < 0.05).
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Figure 3. Soleus fatigue. † (K)+K, significantly lower than baseline (P<0.05), ‡ K+DOX,
significantly lower than baseline (P<0.05), * Cr +K significantly lower
than baseline
(P<0.05), and # Cr+DOX, significantly lower than baseline (P<0.05).
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Figure 4. Extensor digitorum longus Fatigue. † K+K, significantly lower than baseline
(P<0.05), ‡ K+DOX, significantly lower than baseline (P<0.05), * Cr+K significantly
lower than baseline (P<0.05), and # Cr+DOX, significantly lower than baseline (P<0.05).
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APPENDIX C
TISSUE MASSES
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Tissue Masses
Group

R-SOL (g)

R-EDL (g)

L-SOL (g)

L-EDL (g)

SED-K-K

0.2241±0.02

0.1820±0.03

0.2109±0.01

.0.1975±0.03

SED-Cr-K

0.2606±0.03

0.2106±0.03

0.1992±0.03

0.1942±0.01

SED-Cr-DOX

0.2300±0.02

0.2006±0.03

0.1976±0.01

0.1919±0.01

SED-K-DOX

0.2085±0.01

0.1940±0.02

0.1772±0.02

0.1743±0.04

RT-K-K

0.2708±0.04

0.2359±0.02

0.2496±0.07

0.2227±0.04

RT-Cr-K

0.2532±0.04

0.2690±0.04

0.2332±0.023

2329±0.01

RT-Cr-DOX

0.2666±0.05

0.2309±0.03

0.2345±0.02

0.2295±0.02

RT-K-DOX

0.2604±0.06

0.2160±0.02

0.2334±0.02

0.2329±0.03
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APPENDIX E
CREATINE STANDARD CURVE

131
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